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ABSTRACT 
          Plasma prekallikrein (PK) activation exerts both physiological and pathological 
effects within the cardiovascular system and central nervous system (CNS). 
Activated PK (kallikrein) controls cytokine release from human mononuclear cells 
and controls both the intrinsic blood coagulation and the alternative complement 
cascades. The uncontrolled activation of these cascades results in the development 
of pathological pain and angioedema. Increased plasma kallikrein levels are 
associated with hereditary angioedema (HAE) and myocardial infarction, whereby 
kallikrein amplifies the generation of activated factor XII (FXIIa) and bradykinin (BK) 
release from high molecular weight kininogen (HMWK). The primary objective of this 
study was to screen natural products with anti-inflammatory properties for their 
effects on the components namely HMWK, PK, FXIIa and FXIa. Terminalia chebula 
fruit, Terminalia bellirica fruit, Terminalia arjuna fruit, Terminalia brownii bark, 
Terminalia arjuna bark and black tea (Camellia sinensis) extracts inhibited plasma 
kallikrein with IC50 values of 30, 65, 220, 240, 280 and 220 mg/ml, respectively. T. 
chebula fruit, T. arjuna fruit, T. bellirica fruit, T. brownii bark, T. arjuna bark and black 
tea extracts blocked plasma kallikrein on endothelial cells with IC50 values of 15, 20, 
20, 80, 160 and 400 mg/ml, respectively. T. chebula fruit, T. bellirica fruit, T. arjuna 
fruit, T. arjuna bark and black tea extracts blocked FXIIa activity with IC50 values of 
30, 50, 190, 190 and 27 mg/ml, respectively. Arjunoglucosed II and arjunic acid 
blocked FXIIa activity with IC50 values of 370 and 780 μM, respectively. T. chebula 
fruit, T. arjuna fruit and black tea at 50 mg/ml did not affect endothelial cells viability. 
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While red yeast rice (RYR) extract showed no inhibitory effects on plasma kallikrein, 
FXIIa, FXIa and rPRCP, three pure compounds blocked FXIa activity with IC50 values 
of 260, 270 and 400 μM, respectively. Overall, T. chebula fruit, T. arjuna fruit and 
black tea extracts might be useful to improve symptoms of HAE, inflammation and 
thrombosis. The identified inhibitors of FXIIa and FXIa could be used as a lead 
compound to find potent inhibitors of these coagulation factors.  
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I- INTRODUCTION 
 
A. Kallikrein-Kinin system overview  
Kallikrein-kinin system (KKS) is a complex endogenous multiprotein system. The 
components of this system include the precursor kininogen, tissue and plasma 
kallikreins and kinins (BK, des-Arg9 BK and BK1-5). In human, there are two types of 
kininogens, high-molecular-weight kininogen (HMWK) and low-molecular-weight 
kininogen (LMWK). While HMWK is synthesized in the liver and released into the 
plasma, LMWK is produced locally in several tissues. Bradykinin, the major bioactive 
peptide in the KKS, plays an important role in the pathological conditions including 
inflammation, increased vascular permeability, vasodilation, smooth muscle 
contraction, edema, pain and cell proliferation. 
 
B. Kallikrein-Kinin system: roles of plasma Kallikrein 
Human plasma kallikrein is a serine protease enzyme encoded by a single KLKB1 
gene located at the q34-q35 region on the long arm of chromosome 4. Plasma 
kallikrein is predominantly synthesized and secreted by the liver as a zymogen PK, 
which is also known as Fletcher factor (Beaubien et al., 1991).  PK is a single chain 
γ-globulin polypeptide of 619 amino acids with a molecular weight of 85-88 kDa. 
(Fisher C.A et al. 1982; Chung et al. 1986). Normally, 70-90% of the PK zymogen 
circulates in the human blood as a complex with HMWK with stoichiometric molar 
ratio 1:1 and at a range of concentration between 35-50 μg/mL (Mandle et al.1976; 
Reddigari S and Kaplan AP.1989). PK can be activated into kallikrein via the actions 
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of activated factor XII (FXIIa) on negatively charged surfaces, FXIIa in fluid phase 
and PRCP on endothelial cell surface (Figure 1) (Webster, 1968; Mandle, Jr. and 
Kaplan, 1977; Shariat-Madar et al., 2002; Wuepper and Cochrane, 1972).  PK can 
be activated to kallikrein by the cleavage of the Arg371-Ile372 bond. This cleavage 
forms a protein with two-subunits containing the N-terminal heavy chain and the C-
terminal light chain linked by a single disulfide bond located between Cys364 and 
Cys484 (Wuepper and Cochrane, 1972). While the four Apple domains (A1– A4) are 
located in N-terminal heavy region, the protease domain is located in C-terminal light 
chain of PK. In Kallikrein, the catalytic triad is made from His415, Asp464 and 
Ser559 (van der et al., 1982; McMullen et al, 1991).  
            Plasma kallikrein plays crucial roles in various pathological processes of 
diseases associated with inflammation through different systems in the human body 
including plasma KKS (also known as contact system or intrinsic pathway) and 
complement system (Figure 1). Several studies linked the activation of the contact 
system in plasma to the pathogenesis of various diseases (Table 1). Plasma 
kallikrein cleaves HMWK at two sites between Lys362-Arg363 and Arg371-Ser372 to 
liberate BK (Webster and Pierce, 1963; Kerbiriou and Griffin, 1979) and releases the 
cleaved high molecular weight kininogen (HMWKa). HMWKa binds to monocytes 
and induces the production and release of the inflammatory cytokines and 
chemokines that maintain the inflammatory response (Irma M. Sainz et al., 2007). 
The cellular effects of kinins are mediated via two types of G-protein-coupled 
receptors (GPCRs), the B1 receptors (B1R) and B2 receptors (B2R) (Leeb-Lundberg 
LM et al., 2005; Marceau F et al., 1998). 
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 Table 1:  Diseases associated with contact system (plasma KKS) activation: 
Diseases Description References 
Inflammation 
A localized reaction associated 
with swelling, redness, warmth 
and pain. 
Weiser P. et al., 
2010 
Systemic lupus 
erythematosus 
Systemic autoimmune disease 
in which the immune system 
produces antibodies in the body 
attacking healthy cells. 
Weiser P. et al., 
2010 
Hereditary angioedema 
with C1-inhibitor 
deficiency 
An inherited diseases 
characterized by recurrent 
episodes of severe swelling. 
Kaufman N. et al., 
1991; Berrettini M 
et al., 1986 
Rheumatoid arthritis 
Systemic inflammation affects 
joints. 
Rahman M. M et 
al., 1995 
Osteoarthritis 
A common form of arthritis 
cause a mechanical 
abnormalities by affecting joins 
and cartilages. 
Rahman M. M et 
al., 1995 
Ulcerative colitis 
An inflammatory bowel disease 
characterized by inflammation 
and ulcers in the digestive tract. 
Stadnicki A. et al., 
1997 
Psoriasis 
A chronic disease in which the 
skin cells are growing rapidly. 
Weiser P. et al., 
2010 
Diabetic retinopathy 
A diabetic eye disease caused 
by the damage to the retina. 
Phipps J. A et al., 
2008; Clermont A., 
2011 
Macular edema 
A swelling of the macula of the 
eye. 
Phipps J. A et al., 
2008; Clermont A., 
2011 
Sepsis 
A life-threatening blood infection 
that can affect the vital organs. 
Coppola R et al., 
1996 
Systemic amyloidosis 
A disease resulted from the 
accumulation of amyloid protein 
in the organs. 
Maas C. et al., 
2008 
Sickle cell disease 
An inherited form of anemia that 
affects hemoglobin. 
Miller R. L et al., 
1983 
Alzheimer disease 
A chronic brain disease affecting 
memory and other mental 
functions. 
Bergamaschini L 
et al., 2001 
Allergic reaction 
An overreaction resulted from 
immune response to harmless 
substances in the body. 
Oschatz C. et al., 
2011 
Brain ischemia 
Low blood supply to the brain to 
meet metabolic demand. 
Makevnina L.G et 
al., 1994 
Cirrhosis 
Scarring of liver as a result from 
many liver diseases. 
Cugno M. et al., 
1995 
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Figure 1: Roles of plasma kallikrein in hereditary angioedema through (contact 
activation (plasma kallikrein-kinin), complement and fibrinolytic systems.  
[Reproduced with permission from (Zuraw BL. 2008; Morgan BP. 2010), Copyright 
Massachusetts Medical Society]. 
 
 
The B2 receptors are constitutively expressed, while the expression of B1 receptors 
are induced during inflammation (Marceau F, 1995). The BK binds and activates its 
constitutive B2R on endothelial cell membrane leading to an increase in the 
intracellular Ca2+ levels and subsequent production of the endogenous vasodilators 
nitric oxide (NO) and prostacyclin (PGI2) (Zhao et al., 2001; Hong, 1980; Palmer et 
al.1987).  
            Plasma kallikrein is also implicated in the contact surface-mediated activation 
of the intrinsic coagulation pathway (Wuepper, 1973; Saito et al., 1974; Weiss et al., 
Complement system Contact activation system  (plasma Kinin-Kallikrein system, intrinsic pathway) 
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1974; Colman et al., 1975; Griffin & Cochrane, 1976), in which it drives a positive-
feedback loop by activating more FXII. In the complement system, plasma kallikrein 
activates the alternative complement pathway (an innate component of the immune 
system) and catalyzes the secondary cleavage of α-FXIIa to yield β-FXIIa, which 
activates the classical complement pathway (a group of plasma proteins that 
mediate the specific antibody response) (Discipio R.G. 1982; Ghebrehiwet et al. 
1981). However, the activation effect produced through either of these two 
complement system pathways resulted ultimately in the generation of chemotactic 
mediators (C3a and C5a) and opsonins (C3b, a molecule that enhances 
phagocytosis). While chemotactic mediators recruite the inflammatory cells, 
opsonins initiate the membrane attack pathway to form membrane-attack complex 
C5b-9 (Muller-Eberhard.1988). In addition to its complement activating properties, 
plasma kallikrein can also stimulates neutrophil chemotaxis, aggregation, oxidative 
metabolism and neutrophil elastase release (Kaplan et al., 1972; Schapira et 
al.1982; Wachtfogel et al.1983). 
 
C. Kallikrein-Kinin system: roles of Factor XII  
       Coagulation FXII is a serine protease enzyme that is produced and released by 
the hepatocytes. It is encoded by the F12 gene, which has been mapped to 
chromosome 5 in humans (Citarella F et al. 1988). The FXII circulates in the plasma 
as a zymogen. FXII can be activated to its active form, FXIIa on the negatively 
charged surfaces (Moreau ME et al. 2005). C1-INH is a major inhibitor of FXIIa and 
kallikrein (Figure 1). However, insufficient C1-INH levels will cause FXIIa to initiate 
the contact system leading to the local production of bradykinin (Weiss R et al. 
1986). FXIIa might be implicated in hereditary angioedema (HAE) disease through 
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two possible pathways. First, converting PK to kallikrein. On the surface of 
endothelial cells, FXIIa can activate PK in the presence of HMWK into kallikrein, 
which in turn results in the generation of BK (Kaplan AP et al. 2003; Fernando LP et 
al. 2003). Second, FXIIa is a self-activating protease. This means the increase in the 
FXIIa is responsible for the increased BK concentrations in HAE (Kaplan AP et al. 
2003) (Figure 2). The HMWK is capable of binding and regulating several 
endothelial cell surface proteins. These include cytokeratin 1, gC1qR, and urokinase 
plasminogen activator receptor (uPAR). Furthermore, HMWK binds via its domain 3 
and domain 5 (Joseph K et al. 1999). HMWK binding functions as a cofactor for the 
activation of factor XII as well as PK (Kaplan AP et al. 2003; Mahdi F et al. 2001). 
           
D. Hereditary angioedema (HAE) 
1. General overview of HAE 
Angioedema can be defined as a localized swelling beneath the skin surface in 
different human body sites. It was first described by Milton in 1876. Hereditary 
angioedema (HAE) is an autosomal dominant inherited disease caused by a 
deficiency of the multifunctional enzyme called C1-esterase inhibitor (C1-INH). In 
1882, Quincke published the first study about HAE. Later in 1888, William Osler, 
studied the clinical features of HAE. In 1962, it is detected that C1-INH in the plasma 
of patients with HAE (Landerman et al., 1962). In 1963, the biochemical abnormality 
in the plasma of HAE patients with a deficiency of C1-INH was observed (Donaldson 
and Evans, 1963). The deficiency of C1-INH results from mutations in the C1-INH 
gene (SERPING1). Over 200 different mutations were identified in patients with HAE 
located on chromosome 11 (11q11-q13-1). These mutations resulted either in C1-
INH protein depletion (type I HAE) or synthesis of an abnormal C1-INH protein (type 
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II HAE). Angioedema was classified into different types based on underlying causes 
such as mutations in the cases of HAE, drugs in the cases of acquired angioedema 
or allergic triggers in the cases of allergic angioedema (Table 2). Commonly, two 
different types of HAE are described based on the abnormality in the levels and 
functions of C1-INH. Type I HAE is the most common type, which accounts for up to 
85% of all HAE cases with deficiency in C1-INH plasma levels compared to the 
normal values. Type II HAE accounts for up to 15% of all HAE cases with deficiency 
in C1-INH plasma levels compared to the normal values.  
                Epidemiologic studies showed that the incidence of HAE vary from 1 in 10,000 
to 1 in 150,000 individuals worldwide with no differences between races, ages and 
genders (Frank MM. 2000; Talavera A. 1995). However, HAE is characterized by 
intermittent attacks of localized edema and pain mainly in the extremities, face, larynx 
and gastrointestinal tract without concomitant pruritus. Known triggers of HAE attacks 
include anxiety, stress, trauma and illness such as the cold and flu. The most serious 
attack in an HAE patient is the laryngeal attack because the swelling in this site could 
resulting in airway obstruction causing a death from asphyxiation. Several plasma 
proteinase inhibitors were indicated as deactivators of plasma kallikrein including C1-
INH, α2-macroglobulin (α2M), antithrombin III (AT III), α1-antitrypsin, and α2-anti-
plasmin (α2AP) (Ratnoff O. D et al., 1969; Vennerod A. M and Laake K., 1975).  
                C1-INH is a protease inhibitor that belongs to the serpin superfamily. It is the 
major endogenous inhibitor of the plasma KKS, in which it inhibits FXIIa and Kallikrein 
(Pixley et al., 1985). In 1956, Lepow was the first to find that human plasma 
contained a heat sensitive factor that inhibited C1-INH activity (Lepow et al.1956). In 
addition, C1-INH prevents the activation of the complements C1r and C1s (Ziccardi 
R. J. and Cooper N. R., 1979). The plasma from patients with HAE showed a 
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markedly decreased inhibition toward kallikrein esterolytic and amidolytic activity 
compared to plasma from normal individuals, suggesting C1-INH is one of the major 
endogenous inhibitors of kallikrein (Gigli I et al., 1975; Trumpi-Kalshoven et al., 1978; 
Gallimore et al., 1979). In the plasma, C1-INH exhibited an inhibitory ability to 
inactivate the kallikrein-mediated BK production via forming a 1:1 stoichometric 
complex with kallikrein (Schapira et al., 1983a). During the HAE attack, the depletion 
in the levels of functional C1-INH as a result of the mutations of its encoded gene 
lead to an impaired ability to inhibit its key targets. As results, robust elevation of 
plasma BK levels were generated from HMWK by kallikrein, leading to swelling, 
neutrophil influx, chest pain, increased clotting, shortness of breath, and neurological 
symptoms (Figure 1).  
 
            BK is responsible for most of the symptoms associated with edema in 
patients experiencing acute HAE attacks. The reasons for this are the significant 
increase in the levels of plasma BK, the increase in the venous blood BK from the 
arms with localized HAE, and the elevations in the levels of the activated kallikrein in 
induced blister fluids (Nussberger et al., 1998; Cugno et al., 1997; Shoemaker et al., 
1994; Curd et al., 1980; Nussberger et al. 2002) (Figure 2). Moreover, the levels of 
PK and HMWK in patients with acute HAE attacks were decreased (Schapira et al., 
1983). 
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Table 2: Overview of Hereditary Angioedema (HAE) types and treatment options 
Types Description 
Treatment 
Ref (s) 
Options Advantages Disadvantages 
Hereditary 
Angioedema 
Type I (HAE-I) 
 
 
A) Similarity of HAE type I & type II: 
-Autosomal-dominant inherited (result from 
mutations in C1-inhibitor gene). 
-Occurring in all ages,genders & races. 
-Decrease C4, normal C1q and C3 levels in 
both types. 
B) Dissimilarity: 
-Types I & II represent; 80 to 85% and 15 to 
20% of all HAE cases, respectively. 
-C1-inhibitor level is decrease in type I, while it 
is normal, but 
does not function properly in type II. 
1) Androgens such as danazol, 
oxandrolone and stanozolol 
 
 
2) C1-inhibitor such as Cinryze™ and 
Berinert® 
 
 
 
3) Bradykinin receptor antagonist such as 
Firazyr® 
 
4) Plasma kallikrein inhibitor such as 
Kalbitor® 
 
 
5) Antifibrinolytics such as tranexamic 
acid 
FDA-approved 
Self-administration 
 
 
Treating acute abdominal, facial and 
laryngeal HAE attacks. 
 
 
 
FDA-approved 
Self-administration 
 
FDA-approved 
For patients 16 years of age and 
older. 
 
Can be used if other therapy is not 
appropriate 
 
Liver toxicity, increase in 
cholesterol levels & should not be 
used to treat children 
 
Breakthrough laryngeal or 
abdominal attacks &  serious 
thromboembolic events, 
hypersensitivity, transmitting 
infectious agents 
 
High cost, decrease effects of 
ACE inhibitors 
 
High cost, hypersensitivity 
 
 
Risks of thromboembolism, 
hypotension, and cardiac 
arrhythmias and low efficacy 
Bork K. 
2012 
 
Gandhi, P. 
K et al. 
2008 
 
Bork K et 
al. 2008 
 
 
Banerji A  
et al. 2008 
 
 
Zuraw, B. L 
et al. 2010 
Hereditary 
Angioedema 
Type II (HAE-II) 
 
 
Hereditary 
Angioedema 
Type III (HAE-
III) 
 
-Unknown prevalence, but reported in women 
(mainly). 
- Normal C1-inhibitor, C4, C1q and C3. 
-FXII gene mutations. 
-Associated with pregnancy and the use of 
estrogen-containing oral contraceptives. 
 
 
C1-INH concentrate and Icatibant can be used 
 
Bork K et 
al. 2009 
 
Bouillet L 
et al. 2009 
Acquired 
Angioedema 
Type I (AAE-I) 
A) Similarity of AAE type I & type II: 
-Very rare. 
-Immune complexes that are usually linked to 
an underlying lymphoproliferative disorder 
destroy the function of C1-inhibitor. 
B) Dissimilarity: 
Autoantibodies are present and destroy 
C1-inhibitor function. There is no apparent 
underlying disorder. 
 
 
 
Lymphoproliferative disorder must be targeted 
Unapproved treatment options include antifibrinolytics, androgens or C1-INH concentrate 
 
 
 
Zingale LC 
et al. 2006 Acquired 
Angioedema 
Type II (AAE-II) 
ACE-Inhibitor 
 
-Caused by ACE-Inhibitors such as captopril. 
- Normal C1-inhibitor, C4, C1q and C3. 
-Swelling may commence anywhere from a 
few hours to years after first starting 
medication 
 
ACE-Inhibitors in use must be stopped or change and a bradykinin inhibitor, icatibant can be used 
Weber MA 
et al. 2008 
Idiopathic 
- Normal C1-inhibitor, C4, C1q and C3. 
-  Swelling persist > 6 week (Thyroid 
dysfunction is considered). 
Primarily antihistamines. DHEA. 1-thyroxine for thyroid dysfunction. Prednisone therapy Frigas E et 
al. 2006 
NSAID-
associated 
 
-Angioedema without urticaria 
-Not responsive to H1 antihistamine blockers. 
-Normal C1-inhibitor, C4, C1q and C3. 
 
Avoid NSAIDs and Antifibrinolytics such as tranexamic acid and epsilon-aminocaproic acid 
Pérez C et 
al. 2001 
Allergic 
 
-Swelling results from triggers such as food, 
latex, venom, bee sting, cold, heat, or drug. 
- Normal C1-inhibitor, C4, C1q and C3. 
Antihistamines, adrenaline (epinephrine) and  avoid allergic reaction triggers, Douglas T. 
Johnston. 
2011 
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                 Figure 2: Bradykinin overproduction caused by C1-INH deficiency. Plasma BK levels 
in: 1) six patients with angioedema due to Hereditary C1-Inhibitor Deficiency, 2) four 
patients with angioedema related to angiotensin converting enzyme (ACE) inhibitors, 
3) four patients with urticaria and angioedema that responded to antihistamines 
(histaminergic angioedema). Each circle represents one patient. Solid circles denote 
bradykinin levels during acute attacks of angioedema. Open circles denote levels 
during the remission. The shaded area indicates the normal range of venous plasma 
BK levels (0.2 to 7.1 pM). [Reproduced with permission from (Nussberger et al. 
2002), Copyright Massachusetts Medical Society]. 
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Figure 3: Schematic representation of the mechanisms involved in the liberation of 
the bradykinin (BK) from high molecular weight kininogen (HK), and subsequently 
BK results in increase vascular permeability. FXI: factor XI; FXIa: activated FXI; FXII: 
factor XII; FXIIa: activated factor XII; CTI: corn trypsin inhibitor; SBTI: soybean 
trypsin inhibitor; DFP: Diisopropylfluorophosphate; Long polyp: long-chain 
polyphosphate; rC1-inh: recombinant C1-inhibitor; IL-6: Interleukin 6; IL-1β: 
Interleukin-1 beta; TNFα: tumor necrosis factor alpha; MMP2: matrix 
metalloproteinase-2; MAPK: Mitogen-activated protein kinases; COX-2: 
Cyclooxygenase 2; NOS: nitric oxide synthase. Red circles refer to enzymes 
involved mainly in the liberation of the bradykinin (BK). 
 
BK induced the expression of several inflammatory genes including COX-2, MMPs, 
interleukins (IL-1β, IL-6) as well as chemokines (Zaczynska E et al. 2003; Terzuoli E 
et al. 2014) (Figure 3). The overexpression effects of these genes via BK are 
mediated through the activation of the NF-kB pathway (Terzuoli E et al. 2014). In 
addition, in the airway smooth muscle cells, BK stimulates MMP-2, the enzyme that 
is involved in the inflammatory processes (Zaczynska E et al. 2003; Corbel M et al. 
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2002) (Figure 3). Overall, plasma kallikrein is the major BK liberator, thus it plays a 
crucial role in the pathogenesis of BK-mediated diseases such as hereditary 
angioedema and inflammation. 
 
2. HAE treatment options 
           While plasma kallikrein is the major enzyme for liberation of BK from HMWK, 
four other enzymes indirectly play roles in the liberation of BK from HMWK including: 
FXIIa, activated FXI (FXIa), plasmin, and recombinant prolylcarboxypeptidase 
(rPRCP) (Shariat-Madar Z et al., 2002; Kaplan AP et al., 1997; Merlini PA et al., 
2004; Motta G et al., 1998; Nishikawa K et al., 1992; Molinaro G et al., 2002). 
Because plasma KKS is deeply involved in the pathogenesis HAE, the therapeutic 
options were approved or designed based on their ability to inhibit this pathway. 
Different options were suggested for the treatment and anaphylaxis of HAE 
according to the duration of therapy including acute, short-term and long-term 
therapies (Table 2). Acute treatment strategies include C1-INH (human or 
recombinant) replacement therapy, plasma kallikrein inhibitor (ecallantide), or 
specific bradykinin B2 receptor antagonist (icatibant). While it is not approved for the 
treatment of acute attacks of HAE, the C1-INH agent Cinryze® was the first drug to 
be approved by the US FDA in 2008 for chronic replacement or prophylaxis of C1-
INH in HAE (Cocchio and Marzella, 2009). It works by increasing C1-INH and C4 to 
their normal levels. However, the bradykinin peptidomimetic Icatibant (Firazyr®), was 
approved by the US FDA in 2011 as the first and only self-administered 
subcutaneous drug for treating acute HAE attacks (Cicardi et al. 2010; Aberer et al. 
2014).  Icatibant works by decreasing the vascular permeability via inhibiting the 
binding of bradykinin to its B2 recceptors, which consequently resulted in the 
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reduction of vasodilation effects due to the reduction of NO and PGI2 formation. In 
2009, C1-INH Berinert® and Kalbitor® were approved by the US FDA for the 
treatment of acute attacks of HAE in adults, but not in children (Keating, 2009; Zuraw 
et al., 2010). Ecallantide works by directly inhibiting plasma kallikrein. Several 
limitations associated with Cinryze™, Berinert® and Kalbitor® therapies are reported 
including high cost, risk of type I hypersensitivity reaction or anaphylaxis as well as 
the risk of transmitting plasma derived infections (Lunn et al., 2010; Riedl, 2010). 
Antifibrinolytics such as tranexamic acid can also be used only if other therapies are 
not appropriate. Tranexamic acid works by blocking the conversion of plasminogen 
to plasmin thus abolishes plasmin formation. The use of antifibrinolytics is limited 
now due to their risks of thromboembolism, hypotension, and cardiac arrhythmias as 
well as their low efficacy (Zuraw et al. 2008; Agostoni et al. 2004; Cicardi et al. 2010; 
Dagen et al. 2010).  Although fresh plasma was successfully used for the acute 
treatment and prophylaxis, it is still limited due to the potential threat of worsening 
HAE symptoms by its additional kinins and complement factor contents (Nzeako et 
al. 2001; Agostoni et al. 1992; Galan et al. 1996; McGlinchey et al. 2000; Pekdemir 
et al. 2007). Short-term prophylaxis strategies include C1-INH replacement, oral 
androgens, icatibant, antifibrinolytics, and fresh plasma (Zuraw et al. 2008; Bowen et 
al. 2008; Bowen et al. 2010; Marque´s et al. 2010) (Table 2). 
 
E. Natural products as sources for new drugs 
           Natural products can be simply defined as any substance extracted or 
isolated from nature or living organisms. Broadly, natural products can be classified 
according to their sources such as plants, microbial agents, marine organisms and 
animals. Natural product sources from plants have been routinely used in the 
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treatment of various human diseases for thousands of years ago (Phillipson, J.D et 
al, 2001). More than 70,000 plant species have been screened for their biological 
activities as medicinally agents (Farnsworth, N.R et al, 1991).  
          Black tea (Camellia sinensis) is a species of plant in the Theaceae family. 
While black tea originated in Southeast Asia, it is now cultivated worldwide to 
produce commercial beverages, making it the second most popular after water 
(Graham H.N et al. 1991). The major chemical constituents of black tea are 
polyphenols and include catechins, theaflavins and thearubigins. The major 
catechins in black tea are epigallocatechin gallate (EGCG), epigallocatechin (EGC), 
epicatechin gallate (ECG), epicatechin (EC) (Li S et al. 2012). Black tea extract, and 
its major constituents such as EGCG, exhibited anti-inflammatory effects by reducing 
the lipopolysaccharide (LPS)-induced expression of the inflammatory cytokine 
production such as IL-1β and TNF-α in human cerebral microvascular endothelial 
cells (hCMECs), carrageenin-induced paw edema in rats as well as formaldehyde-
induced arthritis in rats (Nag Chaudhuri A.K. et al. 2005; Jieliang Li et al. 2012). In a 
recent study, black tea extract decreased the rate of blood pressure variation by 
approximately 10% during the nighttime hours, suggesting its cardiovascular benefits 
(Hodgson et al. 2013). 
 
          Terminalia belongs to the family Combretaceae, native to Asia includes India 
and China. There are different species of Terminalia incuding T.chebula, T. bellirica, 
T. arjuna and T. brownii (Figure 4). T. chebula is a deciduous tree growing up to 30 
m tall with a trunk up to 1 m in diameter. It is a popular folk medicine plant that has 
been traditionally used for several purposes such as an anti-inflammatory dietary 
sources, antiplatelet, antioxidant, and for its cardiovascular effects (Zia-Ul-Haq M. et 
al. 2012, Dolly Singh et al. 2012, Hyun-Ho Lee et al. 2015, Gautam M. K. et al. 
  15 
2013). In Ayurvedic Indian traditional medicine, T.chebula, as well as T. bellirica are 
two components of triphala, a popular Ayurvedic formulation that is used for several 
purposes including eye diseases, diabetes and improvement in digestion (Ayurvedic 
pharmacopoeia committee, 2003). T.chebula was indicated to have a strong anti-
inflammatory activity in many studies. For example, the polyherbal formulation called 
Aller-7, which is the combination of seven medicinal plant extracts including T. 
chebula and T. bellirica extracts showed a strong anti-inflammatory effect (Pratibha 
et al. 2004). In an acetic acid-induced colitis model, it was noted that T. chebula 
could increase the antioxidant effects and decrease free radical formation (Gautam 
M. K et al. 2013).  
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Figure 4: Schematic representation the scientific classification of Terminalia 
species used in this study and their distributions. 
 
 
 
 
 
           Red yeast rice (RYR) is the fermented product obtained after red yeast 
(Monascus purpureus) is grown on rice. It had been used in China for centuries as a 
food flavoring as well as a medicinal product (Wang J et al. 1997). RYR has been 
used as a food colorant and preservative and in a traditional Chinese medicine. It 
was described by the Pharmacopeia of the People’s Republic of China as a body 
invigorative, helping in digestion, and revitalizing blood circulation (Erdogrull O et al. 
2004). Several preparations of RYR are commercially available including Cholestin, 
Xuezhikang and Zhibituo. These preparations were found to exhibit improvements 
Plant Scientific classification  
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on lipid profile including significant reductions of serum total cholesterol, LDL-
cholesterol, triglyceride (TG), and provide an increase in HDL-cholesterol (Liu JP et 
al. 2006). Xuezhikang is a partially purified extract of fermented red yeast rice 
(Monascus purpureus). It is composed of 13 natural statins, unsaturated fatty acids, 
ergosterol, amino acids, flavonoids, alkaloid and trace elements. Xuezhikang also 
exhibited lipid lowering and anti-inflammatory properties (Heber D et al. 1999).  
 
 
 
F. Objective 
 
 
           Kallikrein levels are indicated to be associated with hereditary angioedema 
and myocardial infarction, whereby kallikrein amplifies the generation of activated 
factor XII (FXIIa) and bradykinin (BK). BK is responsible for most of the symptoms 
associated with edema in patients with acute HAE attacks. Thus, BK plays a crucial 
role in the pathophysiology and clinical manifestations of HAE. We hypothesized that 
kallikrein inhibitors represent a novel class of drugs for reducing inflammation with a 
broad spectrum of activity.  
          The primary objective of this study was to screen natural products known for 
their anti-inflammatory and cardiovascular properties for their effects on kallikrein-
kinin system using amidolytic kallikrein/FXIIa assays to explore their potential 
implications in the treatment of Hereditary Angioedema. 
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II- EXPERIMENTAL METHODS 
A. Materials 
1) Reagents 
 
Human pulmonary artery endothelial cells (HPAECs), Medium 200, low serum 
growth supplement, trypsin-EDTA (ethylenediaminetetraacetic acid), Trypsin-
neutralizing solution (TNS), S2 cells and Hygromycin B were purchased from 
Invitrogen Life Technologies (Grand Island, NY, USA). SFX-insect serum free insect 
cell culture medium and DPBS (Dulbecco's phosphate-buffered saline) were 
purchased from Thermo Scientific (Logan, UT, USA). Single-chain HK, human PK, 
human plasma α-kallikrein and human FXIIa were purchased from Enzyme 
Research Laboratories (South Bend, IN, USA). S2302; BIOPHEN CS-31 (02) was 
purchased from Aniara (Mason, OH, USA). Ala-Pro-paranitroaniline (APpNA) was 
purchased from Bachem (Torrance, CA, USA). Diethylaminoethyl (DEAE) cellulose 
was purchased from Whatman (Fairfield, NJ, USA). Spectra/Por® Dialysis 
Membrane (MWCO 6-8 kDa) was purchased from Spectrum Laboratories, Inc 
(Rancho Dominguez, CA, USA), SP Sephadex 50-120 and dimethyl sulfoxide 
(DMSO) were purchased from Sigma (St. Louis, MO, USA). 
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Table 3: Enzymes and substrates used in the study: 
 
 
2) Cell Cultures 
 
Using the endothelial cell culture, HPAEC was obtained and cultured in growth 
medium 200 supplemented with low serum growth supplement according to the 
manufacturer’s protocol (Invitrogen, NY) into 96 well culture plates (BRAND; 
Wertheim, Germany) and incubated in a CO2 controlled incubator (5% CO2) at 37°C 
overnight.  
Using the Schneider (S2) cell culture, S2 cells were derived from Drosophila 
melanogaster embryo.  PRCP-transfected S2 cells with a plasmid were cultured in 
20 mL of HyQ SFX–Insect cell culture medium (Hyclone, Utah) supplemented with 
1mM Hygromycin (Invitrogen, Carlsbad, CA) in 75 cm2 tissue culture flasks (Fisher 
Scientific, PA) in a temperature controlled incubator (23 ºC) (Chajkowski et al. 2011).  
Once the cells were confluent, 1 flask of cells was subcultured to 3 flasks and from 3 
to 10 flasks, and incubated overnight.  
 
 
Enzyme 
Substrate 
Name Sequences 
Kallikrein and FXIIa S2302 H-D-Pro-Phe-Arg-p-Nitroanilide, 
FXIa S2366 Glu-Pro-Arg-p-Nitroanilide 
rPRCP APpNA H-Ala-Pro-pNA 
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B. Extraction 
            Black tea was extracted with deionized (DI) water (Tea was soaked in boiling 
water for 15 minutes, 4 g/10 ml DI water). After 15 min it was filtered and the filtrate 
was lyophilized and kept in -20 ºC freezer until fractioned and analyzed.  
           Terminalias extracts, red yeast rice extract and their isolated compounds 
were prepared and processed by the National Center for Natural Products Research 
(NCNPR) at the Univesity of Mississippi. All other natural product extracts were 
prepared according to the method of Radwan MM et al. 2014. 
 
 
C. Effects of natural product extracts and/or bioactive compounds on plasma 
kallikrein activity in fluid phase 
In this experiment the effect of the extracts or the pure compounds on the rate of 
S2302 hydrolysis by kallikrein was assessed. Kallikrein (2 nM) was incubated with 
increasing concentrations of the extracts (20 mg/ml to 500 mg/ml) or the pure 
compounds (1 µM to 1000 µM) in the presence of 0.4 mM of the substrate (H-D-Pro-
Phe-Arg- p-Nitroanilide, S2302) in HEPES-carbonated buffer (137 mM  NaCl, 3 mM 
KCl, 12 mM NaHCO3, 14.7 mM HEPES, 5.5 mM Glucose, 0.1% Gelatin, 2 mM 
CaCl2, 1 mM MgCl2, 7.1 pH)  for 1 hour at 37 ºC. The negative control has the same 
reaction mixture except kallikrein. The positive control contains the same reaction 
mixture component except the extract or the pure compound. The same increasing 
concentrations of the extracts plus the substrate in HEPES-carbonated buffer 
without kallikrein was used as a color control. However, the substrate hydrolysis was 
assessed spectrophotometrically at 405 nm. Kallistop™ (100 μM, equivalent to 77.4 
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μg/ml) was used as a reference kallikrein inhibitor and HEPES-carbonated buffer 
was used for the negative control. 
 
D. Effects of natural product extracts and/or bioactive compounds on plasma 
kallikrein on endothelial cells 
To determine the biological action of plant extracts or the pure compounds to inhibit 
kallikrein activity on endothelial cell surface, HPAECs were grown in medium 200 
supplemented with low serum growth supplement (contains fetal bovine serum, 
basic fibroblast growth factor, heparin, hydrocortisone, and epidermal growth factor) 
overnight in 96 well plates. Then, the cells were incubated with 1% gelatin buffer to 
block the surface of the plate and the remaining cell surface to prevent nonspecific 
binding of HMWK during subsequent steps. After one hour incubation period, the 
cells were incubated with 30 nM HMWK for 1 hour at 37 ºC, and followed by 30 nM 
of PK with increasing concentrations of the extracts (20 mg/ml to 500 mg/ml) or the 
pure compounds (1 µM to 1000 µM) for 1 hour at 37 ºC. Finally, cells were incubated 
with 0.5 mM of S2302 in HEPES-carbonated buffer for 1 hour at 37 ºC. Cells were 
washed gently with HEPES-carbonated buffer three times between each incubation 
step and the substrate hydrolysis was assessed spectrophotometrically at 405 nm.  
 
E- Effects of natural product extracts and/or bioactive compounds on FXIIa 
activity in fluid phase 
Next, investigations were peformed to determine the biological action of the plant 
extracts and pure compounds on FXIIa. Increasing concentrations of the extracts (20 
mg/ml to 500 mg/ml) or the pure compounds (1 µM to 1000 µM) were incubated with 
17 nM of FXIIa and 0.4 mM of the substrate (H-D-Pro-Phe-Arg- p-Nitroanilide, 
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S2302) in HEPES-carbonated buffer at 37 ºC for 1 hour. The negative control had 
0.4 mM of S2302 in HEPES-carbonated buffer. The positive control had 0.4 mM of 
S2302 plus 17 nM of FXIIa without the extract or the pure compound. The color 
controls have the same increasing concentrations of the extracts plus 0.4 mM of 
S2302 in HEPES-carbonated buffer without FXIIa enzyme. Then the hydrolysis was 
measured at wavelength 405 nm using absorbance plate reader. Corn trypsin 
inhibitor (9 μM, equivalent to 126 μg/ml) was used as a reference FXIIa inhibitor. 
 
F- Effects of natural product extracts and/or bioactive compounds on FXIIa-
induce HPAEC migration 
After plating 5,000 of HPAECs per well, the cells were incubated overnight to 
achieve 90 % confluence. HPAEC monolayers were scratched using 200 µL pipette 
tip, and serum-containing media was added to each well. Reference points near the 
scratch were marked using the marker. Wells were washed with 100 µL of DPBS 
(Dulbecco's phosphate-buffered saline) buffer two times to remove the floating cells 
resulted from the scratch. First, to determine the magnitude of the pharmacological 
effect, cells were incubated with various concentrations of the plant extracts. 
However, 100 µL of growth medium in the presence of increasing concentrations of 
the plant extract was added to the wells. Other types of treatment include the 
following: 1) 100 µl of growth medium per well were used as positive control, 2) 240 
nM of FXIIa in 100 µl total volume of growth medium per well were used to induced 
HPAECs migration, 3) selected plant extract concentrations were added to 100 µl 
total volume of growth medium per well in the absence of 240 nM FXIIa, 4) selected 
plant extract concentrations were added to 100 µl total volume of growth medium per 
well in the presence of 240 nM FXIIa. Images of the wells were taken at 0 hr with a 
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phase contrast microscope. After 24 hrs, growth medium of all the wells was 
decanted and wells were washed with 100 µL DBPS two times, 100 µL of cold 
methanol were added to each well and incubated at 4 °C for 5 mins. Next, the cold 
methanol was decanted and 70 µL of diluted crystal violet dye (0.1%) in DBPS was 
added to each well and incubated for 30 minutes at room temperature. The loose 
from the cells dye was washed by the water and the wells allowed to dry for 1 hr at 
room temperature. Serial images of the reference points at the beginning and during 
the migration close to the scratch (wound) area were taken. The effects of the plant 
extract on the migration rate were quantified by comparing the images using imageJ. 
Each group had wells in triplicates, and each experiment was repeated 3 times.  
 
G- Effects of natural product extracts and/or bioactive compounds on rPRCP 
activity in fluid phase 
1- Transfected Drosophila Schneider (S2) cell culture 
The enzyme rPRCP was purified form Schneider (S2) cells in which S2 cells were 
derived from Drosophila melanogaster embryo. S2 cells were transfected previously 
with a plasmid carrying the human PRCP gene, as described previously (Shariat-
Madar Z et al. 2004). S2 cells were cultured in 20 mL of HyQ SFX–Insect cell culture 
medium (Hyclone, UT) and hygromycin B (Invitrogen, CA) were added in a 
concentration of 1 mM to facilitate the selective growth of cells with the rPRCP1 
plasmid in 75 cm2 tissue culture flasks (Fisher Scientific, PA) at 23 ºC in atmospheric 
air. Once the cells were confluent, 1 flask of cells was subcultured to 3 flasks and 
from 3 flasks to 10 flasks and incubated at 23 ºC in atmospheric air. 
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2- rPRCP purification from transfected S2 cells 
 2.1 S2 cells induction 
In the induction step, the suspended S2 cells from 12 flasks were transferred to 
several 50 mL polypropylenecentrifuge tubes and centrifuged for 10 minutes at 350x 
g at 23 °C. The cell pellet was resuspended in the induction medium, HyQ SFX-
Insect cell culture medium (Hyclone, UT) in which 1 mM hygromycin B (Invitrogen, 
CA) and 0.66 mM CuSO4 (CuSO4 induced human PRCP gene through 
metallothionein gene to express rPRCP (Lys46-His496) protein into the supernatant) 
was added and incubated in dark for 48 hours at 23 °C on a shaker with circular or 
rocker shaking motion for gentle mixing and oxygenating the cells.  
 
 2.2 Dialysis I 
Following 48 hours of incubation, the supernatant was collected from the cell 
suspensions via centrifugation for 10 min at 350x g at 23 °C. Then the supernatant 
was transferred to spectra/por 1 dialysis membrane (Spectrum Laboratories, CA). 
This tubing membrane has 6-8 kDa molecular weights cut off. The membrane was 
prepared for dialysis according to the manufacturer's instructions. The supernatant 
was dialyzed in 4 liters of 1x Tris Buffer (10 mM Tris, 25 mM NaCl, 0.5 mM EDTA, 
0.5 mM β-mercaptoethanol; pH 7.1) overnight at 4 °C with two times buffer changes 
after 4 to 6 hrs.   
 
 2.3 Anion exchange chromatography 
In anion exchange chromatography, ten grams of diethylaminoethyl (DEAE) 
cellulose resin (Whatman, AZ) was soaked in 40 ml of 1x Tris Buffer (10 mM Tris, 25 
mM NaCl, 0.5 mM EDTA, 0.5 mM β-mercaptoethanol; pH 7.1) and the buffer was 
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changed once after 30 mins. A DEAE-cellulose solution was added to column (3.5 
cm inner diameter X 25 cm length) and then packed and equilibrated with 3 times 
the bed volume (20 to 22 mL) of 1x Tris buffer. The dialysate was loaded into the 
column. The column was subsequently washed with 3 times the bed volume of 1x 
Tris buffer.   
 
 2.4 Dialysis II 
The flow-through from the sample and washing steps were pooled and transferred 
into dialysis tubing membrane. The sample was dialyzed in 1x CH3COONa buffer 
(10 mM CH3COONa, 0.5 mM EDTA, 0.5 mM β-Mercaptoethanol; pH 4.8) overnight 
in 4°C with two times buffer changes after 4 to 6 hrs.   
 
 2.5 Cation exchange chromatography 
In the cation excharge chromatography, 0.45 g of sephadex-SP 150-20 column resin 
(Sigma-Aldrich Co., MO) was soaked in 40 ml and equilibrated in 1x CH3COONa 
buffer (10 mM sodium acetate trihydrate, 0.5 mM EDTA, 0.5 mM β-mercaptoethanol, 
4.8 pH) for one hour. The buffer was changed once after 30 minutes. The sephadex-
SP solution was added to a column (1.5 cm inner diameter X 25 cm length) and then 
packed and equilibrated with 3 times the bed volume (30 to 35 mL) of 1x 
CH3COONa buffer at 4°C using a cold room. The dialysate was loaded into the 
column and the column was washed with 1x CH3COONa buffer. rPRCP adsorbs to 
the column. The bound rPRCP protein was recovered from the column by eluting 
with 0.2 M KCl (in 1x CH3COONa) (in a volume equivalent to 3 times the bed 
volume). The rPRCP obtained was stored at 4 °C to be used in the activity assay. 
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3- rPRCP activity assay 
To determine the inhibitory effects, increasing concentrations of the extracts (20 
mg/ml to 500 mg/ml) or the pure compounds (1 µM to 1000 µM) were incubated with 
the purified rPRCP (30 µg/ml) and 0.5 mM of the substrate H-Ala-Pro-pNA (APpNA) 
in HEPES-carbonated buffer for 1 hour at 37 ºC. The negative control has only 0.5 
mM of APpNA in HEPES-carbonated buffer. The positive control has 0.5 mM of 
APpNA plus an appropriate volume of the purified rPRCP without the extract. The 
color controls have the same increasing concentrations of the extract plus 0.5 mM of 
APpNA in HEPES-carbonated buffer without rPRCP. The substrate hydrolysis was 
assessed spectrophotometrically at 405 nm. Z-Pro-Prolinal (10 mM, equivalent to 3.3 
mg/ml) was used as a reference rPRCP inhibitor. 
 
H. Effects of natural product extracts and/or bioactive compounds on FXIa 
activity in fluid phase 
To determine the pharmacological effects of the plant extracts and the pure 
compounds to inhibit FXIa, increasing concentrations of the extracts (20 mg/ml to 
500 mg/ml) or the pure compounds (1 µM to 1000 µM) were incubated with 2 nM of 
FXIa and 0.291 mM of the substrate (Glu-Pro-Arg-p-Nitroanilide, S2366) in HEPES-
carbonated buffer for 1 hour at 37 ºC. Then the substrate hydrolysis was assessed 
spectrophotometrically at 405 nm.  
 
I. Effects of natural product extracts and/or bioactive compounds on FXIa 
activity on HPAEC   
To determine the pharmacological effects of the plant extracts and the pure 
compounds to inhibit the production of FXIa on the surface of endothelial cells, 
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HPAECs were grown in medium 200 supplemented with low serum growth 
supplement overnight at 37 oC in 96 well plates. The cells were washed three times 
with HEPES-carbonated buffer and blocked with 1% gelatin for 1 hour at 37 oC to 
prevent non-specific binding. After three times washing with HEPES-carbonated 
buffer, HPAEC were incubated with 80 nM of HK for 1 hour at 37 oC.  At the end of 
incubation, cells were washed three times with HEPES-carbonated buffer to remove 
the unbound HK and then treated with 40 nM of FXI. After incubation for one hour at 
37 oC, cells were washed three times with HEPES-carbonated buffer and 0.5 mM 
S2366 (Glu-Pro-Arg-pNA·HCl) in HEPES-carbonated buffer was added to determine 
the effects on FXIa activity. Substrate hydrolysis was allowed to proceed for 1 hour 
at 37 oC. FXIa activity was measured as the change in UV absorbance at 405 nm, 
using BioTek ELx800 Absorbance Microplate Reader. 
 
 
 
J. MTT cell viability assay 
 
Cell viability was determined by thiazolyl blue tetrazolium bromide (MTT) colorimetric 
assay. First, 25,000 cells per well of HPAECs were seeded in 96-well culture plates 
cultivated and incubated overnight at 37 °C. Following the addition of 
arjunoglucoside-II for 1 hour, 20 μl of filtered MTT solution containing 5 mg/ml MTT 
in serum free medium was added to each well. After 4 h of incubation at 37 °C, the 
medium was aspirated and the cells were lysed by the addition of 150 μL per well 
MTT solvent containing 4 mM HCl and 0.1% Nondet P-40 (NP40) in 100% 
isopropanol. Plates were covered with aluminium foil and placed on an orbital shaker 
for 15 minutes at room temperature. The optical density (OP) of each sample was 
measured in a microplate reader using a reference wavelength of 570 nm with 
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background subtraction at 690 nm. Each group had three wells and each experiment 
was replicated 3 times.   
 
K. Statistical analysis  
The mean ± SEMs from the bioassays of plasma kallikrein, rPRCP, and FXlla, FXIa 
and kallikrein formed on cells were analyzed with nonlinear regression in GraphPad 
Prism 6.0. GraphPad Software, Inc., USA. Experiments were performed at least 
three times in duplicate or triplicate. Data was analyzed using one-way analysis of 
variance (ANOVA). For all comparisons, statistical significance was defined as *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001 or ****P ≤ 0.0001. 
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III-RESULTS 
A) Effects of natural product extracts and/or their bioactive compounds on 
plasma kallikrein activity: 
           Plasma kallikrein plays an important role in the pathogenesis of hereditary 
angioedema in which the levels of plasma kallikrein-mediated bradykinin production 
is increased due to the depletion in the levels of its major endogenous, C1-INH. So, 
in order to develop a safe and effective plasma kallikrein inhibitor that could inhibit 
kallikrein-mediated generation of BK from HMWK, we have screened several natural 
plant extracts listed in (Table 4) for their effects on enzymes involved either directly 
such as plasma kallikrein or indirectly such as FXIIa, and rPRCP in the liberation of 
BK from HMWK. These natural products were selected based on their anti-
inflammatory and cardiovascular effects shown in the literature as well as their safety 
and availability (Table 3). 
Table 4: Screened natural products and their reported health benefits. 
Plants Species 
Part 
used  
Health benefits References 
Anise 
Pimpinella 
anisum 
Fruit Antiinflammatory and antioxidant  
Al-Ismail KM et al. 2004, 
Monika M. 2010 
Basil 
Ocimum 
basilicum 
Herb Antiinflammatory and antioxidant 
Gülçin I et al. 2007, 
Monika M. 2010 
Black pepper 
Piper 
nigrum 
Fruit Antioxidant, hypolipidemic effect, antiinflammatory 
Srinivasan K. 2007, 
Wakade SA et al. 2008, 
Vijayakumar RS et al. 
2002,  
Monika M. 2010 
Cardamon 
Elettaria 
cardamomum 
Fruit 
Antioxidant, antihypertensive and antiplatelet 
aggregation, antiinflammatory 
Suneetha WJ et al. 2005, 
Gilani AH et al. 2007, 
Verma SK et al. 2009, 
Monika M. 2010 
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Cayenne 
pepper 
Capsicum 
annuum 
Fruit 
Antiinflammatory, decrease cholesterol levels 
and Antioxidant 
Liang YT et al. 2013, 
Wang Q et al. 2014, 
Monika M. 2010 
Cinnamon 
Cinnamomu
m cassia 
Bark 
Antioxidants, antiinflammatory, reduce blood 
pressure, , increased coronary blood flow, 
cardiac contractile force and beating rate, 
reduced peripheral vascular resistance and 
improved lipid profile 
Wang YS.1983, 
Sharma SR et al. 1996, 
Kim NJ et al. 1999,2000, 
Kamal A et al. 2009, 
Youn HS et al. 2008, 
Monika M. 2010 
 
Clove 
Syzygium 
aromaticum 
Fruit 
Antioxidant, anti-inflammatory, hypolipidemic 
effect and antihypertensive 
Peng Z et al. 2013, 
Mnafgui K et al. 2013, 
Monika M. 2010 
Coriander 
Coriandrum 
sativum 
Herb 
 Hypolipidemic effect, antiplatelet activity, 
antiinflammatory 
Chithra V et al. 1997, 
Monika M. 2010, 
Suneetha JW et al. 2005, 
Ramadan FM et al. 2008. 
Cumin 
Cuminum 
cyminum L 
Fruit 
Hypolipidemic effect, antihypertensive, 
antioxidant and Antiinflammatory 
Dhandapani, S et al. 2002, 
Kalaivani P et al. 2013, 
Qinqin Chen et al. 2014, 
Monika M. 2010 
Poppy seed 
Papaver 
somniferum 
Seed Antioxidant 
Cevik-Demirkan A et al. 
2012 
Dill 
Anethum 
graveolens 
Fruit Antiinflammatory and antioxidant 
Al-Ismail KM et al. 2004, 
Monika M. 2010 
Fennel 
Foeniculum 
vulgare 
Fruit Antiinflammatory and antioxidant Choi EM et al. 2004 
Garlic 
Allium 
sativum 
Seed 
Decrease lipid synthesis, blood pressure and 
platelet aggregation and antioxidant  
Monika M.2010 
Rahman K et al. 2006, 
Yu-Yan Y et al. 2001, 
Gebhardt R et al. 1996, 
Tapsell, L.C et al. 2006. 
Ginger 
Zingiber 
officinale 
Rhizome 
Antiinflammatory, antithrombotic, relax blood 
vessels, stimulate blood flow and relieve pain 
Tapsell, L.C et al. 2006. 
Afzal M et. 2001, 
Monika M. 2010 
Henna 
Lawsonia 
inermis 
Herb Antiinflammatory and antioxidant 
Ali BH et al. 1995, 
Mikhaeil BR et al. 2004. 
Marjoram 
Origanum 
majorana 
Herb Antiinflammatory and antioxidant 
Zheng, W et al. 2001, 
M.B. Hossain et al. 2011, 
Monika M. 2010 
Mentha 
Mentha 
spicata 
Herb Antiinflammatory P. Arumugam et al. 2008 
Nutmeg 
Myristica 
fragrans 
Fruit Antiinflammatory and antioxidant 
Kareem, M. A et al. 2013, 
Monika M. 2010 
Oregon 
Origanum 
vulgare 
Herb Antiinflammatory and antioxidant 
Zheng, W et al. 2001, 
M.B. Hossain et al. 2011, 
Monika M. 2010 
Paprika  Fruit Antiinflammatory Monika M. 2010 
Rosemary 
Rosmarinus 
officinalis 
Herb Antiinflammatory and antioxidant 
Zheng, W et al. 2001, 
M.B. Hossain et al. 2011, 
Monika M. 2010 
Thyme 
Thymus 
vulgaris 
Herb Antiinflammatory and antioxidant 
Monika M. 2010 
El-Nekeety AA et al. 2011 
Tea 
Camellia 
sinensis 
Herb 
Preventive effect against atherosclerosis and 
coronary heart disease, antiinflammatory, 
reduce the risk of high blood pressure 
Monika M. 2010, 
Jonathan M et al. 2013,  
K. Nag Chaudhuri et al. 
2005, 
Chatterjee P et al. 2012 
Terminalia 
Terminalia 
arjuna  
Fruit and 
bark 
Antihypertensive, Antioxidant, effective in 
heart diseases 
Maulik SK et al. 2012, 
Chander R et al, 2004 
Terminalia 
bellirica 
Fruit Anti-inflammatory and antinociceptive 
Sabina EP et al. 2008, 
Sireeratawong S et al. 2013 
Terminalia 
brownii 
Bark 
 Anti-inflammatory of arjunic acid (terminaia 
brownii constituent) 
Yang MH et al. 2014 
Terminalia 
chebula 
Fruit 
Decrease cholesterol levels, cardiotonic 
effect, antiplatelet effect, antioxidant, anti-
inflammatory 
M. Zia-Ul-Haq et al. 2012,  
Dolly Singh et al. 2012,  
M. K. Gautam et al. 2013,  
Bag A et al. 2013, 
Yang MH et al. 2014, 
Hyun-Ho Lee et al. 2015 
Red yeast 
rice 
 
Red 
fermente
d rice 
Anti-inflammatory, hypolipidemic effects and 
reduced the cardiovascular outcomes 
Heber D et al.1999, 
Liu JP et al. 2006, 
Zhao SP et al. 2007, 
 Ye P et al. 2007 
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           To determine their pharmacological effects on plasma kallikrein activity, we 
have screened thirty plant extracts on kallikrein activity at a selected concentration 
200 mg/ml and accordingly continue our study on the extracts showing promising 
effects (Figure 5).  
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Figure 5: Effect of natural product extracts on plasma kallikrein activity. 200 
mg/ml of thirty natural product extracts were incubated with Kallikrein (2 nM) and 
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was 
detected at 405 nm. Data represent the mean ± SEM of three experiments. [*P ≤ 
0.05, ***P ≤ 0.001, ****P ≤ 0.0001 compare to control] 
 
            T. arjuna fruit and T. arjuna bark were tested at 200 mg/ml. While T. arjuna 
fruit exhibited a significant inhibitory effect on plasma kallikrein by 45%, its bark 
extract showed no effect (Figure 5). T. bellirica fruit, T. brownii bark and T. chebula 
fruit methanol extracts significantly blocked the liberation of paranitroaniline from 
S2302 by plasma kallikrein by 65%, 45% and 85%, respectively (Figure 5). Black 
tea aqueous extract was found to have a significant anti-inflammatory effect 
(Chatterjee P et al. 2012). Additionally, black tea is one of the most common 
beverage worldwide (Graham H.N et al. 1991; Monika Mueller. 2010). Investigations 
indicated that black tea aqueous extract significantly inhibited the hydrolysis of 
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S2302 (0.4 mM) by plasma kallikrein (2 nM) by 55%. At 200 mg/ml, methanol 
extracts of some other natural products also significantly inhibited plasma kallikrein 
activity; black pepper (35%) and cardamom (30%), cayenne pepper (15%), clove 
(15%), cumin (25%), poppy seed (50%), dill (20%), garlic (15%), ginger (17%) and 
rosemary (17%) (Figure 5). Red yeast rice extract was also tested on plasma 
kallikrein activity and showed no effect (Figure 5). Although the majority of the plant 
extracts inhibited kallikrein to various extents, we decided to continue evaluating the 
methanol extracts of all Terminalia species as well as the aqueous extract of black 
tea.  
          The methanol extracts of T. arjuna fruit and T. arjuna bark inhibited the 
hydrolysis of S2302 by plasma kallikrein with IC50 values of 220 mg/ml and 280 
mg/ml, respectively (Figures 6 & 7).  
 
 
Figure 6: Effect of Terminalia arjuna fruit extract on plasma kallikrein activity. 
Increasing concentrations of T. arjuna fruit extract were incubated with Kallikrein (2 
nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 
was detected at 405 nm. Data represent the mean ± SEM of three experiments.  
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Figure 7: Effect of Terminalia arjuna bark extract on plasma kallikrein activity. 
Increasing concentrations of T. arjuna bark extract were incubated with Kallikrein (2 
nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 
was detected at 405 nm. Data represent the mean ± SEM of three experiments.  
 
 
          The methanol extracts of T. bellirica fruit (Figure 8), T. brownii bark (Figure 9) 
and T. chebula fruit (Figure 10) showed inhibitory effects on the hydrolysis of S2302 
by plasma kallikrein with IC50 values of 65 mg/ml, 240 mg/ml and 30 mg/ml, 
respectively. 
 
Figure 8: Effect of Terminalia bellirica fruit extract on plasma kallikrein activity. 
Increasing concentrations of T. bellirica fruit extract were incubated with Kallikrein (2 
nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was 
detected at 405 nm. Data represent the mean ± SEM of three experiments.  
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Figure 9: Effect of Terminalia brownii bark extract on plasma kallikrein activity.  
Increasing concentrations of T. brownii bark extract were incubated with Kallikrein (2 
nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 
was detected at 405 nm. Data represent the mean ± SEM of three experiments.  
 
 
Figure 10: Effect of Terminalia chebula fruit extract on plasma kallikrein 
activity. Increasing concentrations of T. chebula fruit extract were incubated with 
Kallikrein (2 nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of 
hydrolyzed S2302 was detected at 405 nm. Data represent the mean ± SEM of three 
experiments.  
 
           Black tea aqueous extract blocked the activity of plasma kallikrein in fluid 
phase with an IC50 value of 220 mg/ml (Figure 11).  
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Figure 11: Effect of black tea aqueous extract on plasma kallikrein activity. 
Increasing concentrations of black tea aqueous extract were incubated with 
Kallikrein (2 nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of 
hydrolyzed S2302 was detected at 405 nm. Data represent the mean ± SEM of three 
experiments.  
 
 
          We have also tested black tea major compounds including epigallocatechin 
gallate (EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin 
(EC), caffeine and quercetin on plasma kallikrein activity in fluid phase, but all 
showed no effect (Figure 32). 
 
B) Effects of natural product extracts and/or their bioactive compounds on 
plasma kallikrein generation on HPAEC: 
          Plasma kallikrein can be generated from the activation of PK on the 
endothelial cell surface via two stimuli, activated factor XII (FXIIa) on negatively 
charged surfaces and prolylcarboxypeptidase (PRCP) (Figure 1) (Webster, 1968; 
Mandle, Jr. and Kaplan, 1977; Shariat-Madar et al., 2002; Wuepper and Cochrane, 
1972). Thus, we aimed to test the efffects of the plant extracts and the pure 
compounds on kallikrein produced as a result of PK activation on endothelial cell 
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surface. HPAECs were treated with 30 nM HMWK followed by 30 nM PK in the 
presence of increasing concentrations of the extracts or the compounds.  
Both T. arjuna fruit and T. arjuna bark inhibited the hydrolysis of S2302 by kallikrein 
produced on HPAEC with IC50 values of 20 and 160 mg/ml, respectively (Figures 12 
& 13).  
 
Figure 12: Effect of Terminalia arjuna fruit extract on plasma kallikrein formed 
on endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr at 37 
°C. Then the cells were incubated with PK (30 nM) in the presence of increasing 
concentrations of T. arjuna fruit extract for 1 hr at 37 °C. Next, the cells were 
incubated with S2302 (0.5 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed 
S2302 was detected at 405 nm. Data represent the mean ± SEM of three 
experiments.  
 
 
 
 
Figure 13: Effect of Terminalia arjuna bark extract on plasma kallikrein formed 
on endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr at 37 
°C. Then the cells were incubated with PK (30 nM) in the presence of increasing 
concentrations of T. arjuna bark extract for 1 hr at 37 °C. Next, the cells were 
incubated with S2302 (0.5 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed 
S2302 was detected at 405 nm. Data represent the mean ± SEM of three 
experiments.  
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          T. bellirica fruit (Figure 14), T. brownii bark (Figure 15) and T. chebula fruit 
(Figure 16) extracts also inhibited the generation of kallikrein on the endothelial cells 
with IC50 values of 20, 80 and 15 mg/ml, respectively. 
 
Figure 14: Effect of Terminalia bellirica fruit extract on plasma kallikrein 
formed on endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr 
at 37 °C. Then the cells were incubated with PK (30 nM) in the presence of 
increasing concentrations of T. bellirica fruit extract for 1 hr at 37 °C. Next, the cells 
were incubated with S2302 (0.5 mM) for 1 hr at 37 °C. The absorbance of 
hydrolyzed S2302 was detected at 405 nm. Data represent the mean ± SEM of three 
experiments.  
 
 
 
Figure 15: Effect of Terminalia brownii bark extract on plasma kallikrein 
formed on endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr 
at 37 °C. Then the cells were incubated with PK (30 nM) in the presence of 
increasing concentrations of T. brownii bark extract for 1 hr at 37 °C. Next, the cells 
were incubated with S2302 (0.5 mM) for 1 hr at 37 °C. The absorbance of 
hydrolyzed S2302 was detected at 405 nm. Data represent the mean ± SEM of three 
experiments.  
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Figure 16: Effect of Terminalia chebula fruit extract on plasma kallikrein 
formed on endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr 
at 37 °C. Then the cells were incubated with PK (30 nM) in the presence of 
increasing concentrations of T. chebula fruit extract for 1 hr at 37 °C. Next, the cells 
were incubated with S2302 (0.5 mM) for 1 hr at 37 °C 1 hr. The absorbance of 
hydrolyzed S2302 was detected at 405 nm. Data represent the mean ± SEM of three 
experiments.  
 
           
 
          We have tested the activity of two Terminalia isolated compounds on PK 
activation on HMWK bound to HPAECs. Arjunoglucoside II and arjunic acid inhibited 
the generation of kallikrein in a concentration dependent manner with IC50 values of 
300 and 240 μM, respectively (Figures 17 & 18). 
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Figure 17: Effect of arjunoglucoside II on plasma kallikrein formed on 
endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr at 37 °C. 
Then the cells were incubated with PK (30 nM) in the presence of increasing 
concentrations of arjunoglucoside II for 1 hr at 37 °C. Next, the cells were incubated 
with S2302 (0.5 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was 
detected at 405 nm. Data represent the mean ± SEM of three experiments.  
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Figure 18: Effect of arjunic acid on plasma kallikrein formed on endothelial 
cells. HPAECs were incubated with HMWK (30 nM) at 37 °C for 1 hr. Then the cells 
were incubated with PK (30 nM) in the presence of increasing concentrations of 
arjunic acid for 1 hr at 37 °C. Next, the cells were incubated with S2302 (0.5 mM) for 
1 hr at 37 °C. The absorbance of hydrolyzed S2302 was detected at 405 nm. Data 
represent the mean ± SEM of three experiments.  
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          We tested the effect of black tea aqueous extract on the generation of 
kallikrein on endothelial cells and indicated that black tea blocked kallikrein with an 
IC50 value of 400 mg/ml (Figure 19). 
 
 
 
Figure 19: Effect of black tea aqueous extract on plasma kallikrein formed on 
endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr at 37 °C. 
Then the cells were incubated with PK (30 nM) in the presence of increasing 
concentrations of black tea aqueous extract for 1 hr at 37 °C. Next, the cells were 
incubated with S2302 (0.5 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed 
S2302 was detected at 405 nm. Data represent the mean ± SEM of three 
experiments.  
 
 
 
C) Effects of natural product extracts and/or their bioactive compounds on 
FXIIa activity:  
          Because FXIIa can activate PK to kallikrein, which in turn results in the 
generation of BK (Kaplan AP et al. 2003; Fernando LP et al. 2003), we aimed to 
determine whether Terminalias and black tea extracts could inhibit FXIIa activity. 
The results indicated that T. arjuna fruit (Figure 20), T. arjuna bark (Figure 21), T. 
bellirica fruit (Figure 22) and T. chebula fruit (Figure 23) extracts blocked FXIIa 
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activity with IC50 values of 190, 190, 50 and 30 mg/ml, respectively. T. brownii bark 
extract showed a minor inhibitory activity in amidolytic system. The extract from T. 
brownii bark had the least inhibitory effect on FXIIa activity. It inhibited FXIIa by 27% 
at highest concentration (Figure 24).  
 
Figure 20: Effect of Terminalia arjuna fruit extract on FXIIa activity. Increasing 
concentrations of T. arjuna fruit extract were incubated with FXIIa (17 nM) and 
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was 
detected at 405 nm. Data represent the mean ± SEM of three experiments.  
 
 
 
 
Figure 21: Effect of Terminalia arjuna bark extract on FXIIa activity. Increasing 
concentrations of T. arjuna bark extract were incubated with FXIIa (17 nM) and 
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was 
detected at 405 nm. Data represent the mean ± SEM of three experiments. 
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Figure 22: Effect of Terminalia bellirica fruit extract on FXIIa activity. Increasing 
concentrations of T. bellirica fruit extract were incubated with FXIIa (17 nM) and 
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was 
detected at 405 nm. Data represent the mean ± SEM of three experiments.  
 
 
Figure 23: Effect of Terminalia chebula fruit extract on FXIIa activity. Increasing 
concentrations of T. chebula fruit extract were incubated with FXIIa (17 nM) and 
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was 
detected at 405 nm. Data represent the mean ± SEM of three experiments.  
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Figure 24: Effect of Terminalia brownii bark extract on FXIIa activity. Increasing 
concentrations of T. brownii bark extract were incubated with FXIIa (17 nM) and 
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was 
detected at 405 nm. Data represent the mean ± SEM of three experiments.  
 
 
 
 
 
Figure 25: Effect of black tea aqueous extract on FXIIa activity. Increasing 
concentrations of black tea aqueous extract were incubated with FXIIa (17 nM) and 
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was 
detected at 405 nm. Data represent the mean ± SEM of three experiments.  
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         Black tea aqueous extract blocked the activity of FXIIa with an IC50 value of 27 
mg/ml (Figure 25). Black tea major compounds including epigallocatechin gallate 
(EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin (EC), 
caffeine and quercetin were ineffective in inhibiting FXIIa activity (Figure 32). 
 
            On the effects of Terminalia pure compounds, among all tested compounds, 
arjunoglucoside II and arjunic acid showed inhibitory effects with IC50 values of 370 
and 780 µM, respectively (Figures 26 & 27). 
 
Figure 26: Effect of arjunoglucoside II on FXIIa activity. Increasing 
concentrations of arjunoglucoside II were incubated with FXIIa (17 nM) and S2302 
(0.4 mM) for 1 hr at 37 °C (structure is shown). The absorbance of hydrolyzed S2302 
was detected at 405 nm. Data represent the mean ± SEM of three experiments.  
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Figure 27: Effect of arjunic acid on FXIIa activity. Increasing concentrations of 
arjunic acid were incubated with FXIIa (17 nM) and S2302 (0.4 mM) for 1 hr at 37 
°C. The absorbance of hydrolyzed S2302 was detected at 405 nm. Data represent 
the mean ± SEM of three experiments.  
 
 
D) Effects of natural product extracts and/or their bioactive compounds on 
recombinant PRCP activity:  
          Because PRCP is also an activator of PK to kallikrein on the endothelial cells, 
we aimed to determine whether Terminalias and black tea extracts could inhibit 
PRCP activity. Using recombinant human PRCP (rPRCP), we tested the methanol 
extracts of all Terminalia species as well as the aqueous extract of black tea on 
rPRCP activity. As described above in methods, increasing concentrations of 
extracts were incubated with rPRCP (30 µg/ml) and the substrate APpNA (0.5 mM). 
T. arjuna fruit, T. chebula fruit and T. brownii bark extracts blocked the release of 
paranitroaniline from APpNA by rPRCP with an IC50 values of 150, 120 and 280 
mg/ml, respectively (Figures 28, 29 & 30). T. arjuna bark and T. bellirica fruit did not 
inhibit rPRCP activtity. 
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Figure 28: Effect of Terminalia arjuna fruit extract on rPRCP activity. Increasing 
concentrations of T. arjuna fruit extract were incubated with rPRCP (30 µg/ml) and 
the substrate APpNA (0.3 mM) for 1 hr at 37 °C. The absorbance of paranitronilide 
was detected at 405 nm. Data represent the mean ± SEM of three experiments. 
 
 
Figure 29: Effect of Terminalia chebula fruit extract on rPRCP activity. 
Increasing concentrations of T. chebula fruit extract were incubated with rPRCP (30 
µg/ml) and the substrate APpNA (0.3 mM) for 1 hr at 37 °C. The absorbance of 
paranitronilide was detected at 405 nm. Data represent the mean ± SEM of three 
experiments. 
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Figure 30: Effect of Terminalia brownii bark extract on rPRCP activity. 
Increasing concentrations of T. brownii bark were incubated with rPRCP (30 µg/ml) 
and the substrate APpNA (0.3 mM) for 1 hr at 37 °C. The absorbance of 
paranitronilide was detected at 405 nm. Data represent the mean ± SEM of three 
experiments. 
 
 
         Black tea aqueous extract inhibited rPRCP with IC50 value of 160 mg/ml 
(Figure 31). Black tea major compounds showed no effect on rPRCP activity 
(Figure 32). 
 
Figure 31: Effect of black tea aqueous extract on rPRCP activity. Increasing 
concentrations of black tea aqueous extract were incubated with rPRCP (30 µg/ml) 
and the substrate APpNA (0.3 mM) for 1 hr at 37 °C. The absorbance of 
paranitronilide was detected at 405 nm. Data represent the mean ± SEM of three 
experiments. 
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Figure 32: Effect of black tea pure compounds on plasma kallikrein, FXIIa and 
rPRCP activities. Panel.A Increasing concentrations of epigallocatechin gallate 
(EGCG), epigallocatechin (EGC), epicatechin gallate (ECG) and epicatechin (EC) 
were incubated with Kallikrein (2 nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The 
absorbance of hydrolyzed S2302 was detected at 405 nm. Data represent the mean 
± SEM of three experiments. Panel.B Increasing concentrations of EGCG, EGC, ECG 
and EC were incubated with FXIIa (17 nM) and S2302 (0.4 mM) for 1 hr at 37 °C. 
The absorbance of hydrolyzed S2302 was detected at 405 nm. Data represent the 
mean ± SEM of three experiments. Panel.C Increasing concentrations of EGCG, 
EGC, ECG and EC were incubated with rPRCP (30 µg/ml) and the substrate APpNA 
(0.5 mM) for 1 hr at 37 °C. The absorbance of paranitronilide was detected at 405 
nm. Data represent the mean ± SEM of three experiments. 
 
E) Effects of natural product extracts and/or their bioactive compounds on 
HPAEC viability using the MTT assay:  
          To test weather the inhibitory effects of tested extracts on the generation of 
plasma kallikrein from PK are not from their effects on HPAEC viability, we 
determined if these extracts were directly toxic to the endothelial cells using the MTT 
assay in which the yellow tetrazole is reduced to purple formazan only in living cells. 
While T. arjuna fruit showed no significant effects on HPAECs viability (Figure 33), 
T. arjuna bark was significantly reduced HPAECs viability by 40% at concentrations 
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equal to or greater than 30 mg/ml (Figure 34).  
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Figure 33: Effect of Terminalia arjuna fruit extract on HPAEC viability using the 
MTT assay. Bar diagrams showing the results of HPAECs viability (% of control). 
HPAECs treated by T. arjuna fruit extract using the MTT assay. The wells containing 
HPAECs were treated T. arjuna fruit extract for its effect on cell viability, and the wells 
containing only a complete growth medium were used as a control. Data represent 
the mean ± SEM of three experiments.  
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Figure 34: Effect of Terminalia arjuna bark extract on HPAEC viability using 
the MTT assay. Bar diagrams showing the results of HPAECs viability (% of control).  
HPAECs treated by T. arjuna bark extract using the MTT assay. The wells containing 
HPAECs were treated T. arjuna bark extract for its effect on cell viability, and the 
wells containing only a complete growth medium were used as a control. Data 
represent the mean ± SEM of three experiments. [****P ≤ 0.0001 compare to % 
control]. 
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         T. bellirica fruit and T. brownii bark were significantly toxic to HPAECs in which 
T. bellirica fruit exhibited its cytotoxic effect in dose-dependent manner (Figure 35) 
and T. brownii bark reduced HPAECs viability at concentartions equal to or greater 
than 20 mg/ml by approximately 40% indicating its toxic effect on endothelial cells 
(Figure 36).  
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Figure 35: Effect of Terminalia bellirica fruit extract on HPAEC viability using 
the MTT assay. Bar diagrams showing the results of HPAECs viability (% of control). 
HPAECs treated by T. bellirica fruit extract using the MTT assay. The wells 
containing HPAECs were treated T. bellirica fruit extract for its effect on cell viability, 
and the wells containing only a complete growth medium were used as a control. 
Data represent the mean ± SEM of three experiments. [*P ≤ 0.05, ***P ≤ 0.001, ****P 
≤ 0.0001 compare to % control]  
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Figure 36: Effect of Terminalia brownii bark extract on HPAEC viability using 
the MTT assay. Bar diagrams showing the results of HPAECs viability (% of control). 
HPAECs treated by T. brownii bark extract using the MTT assay. The wells 
containing HPAECs were treated T. brownii bark extract for its effect on cell viability, 
and the wells containing only a complete growth medium were used as a control. 
Data represent the mean ± SEM of three experiments. [**P ≤ 0.01, ***P ≤ 0.001 
compare to % control] 
 
 
            Interestingly, T. chebula fruit extract exhibited no effects on HPAECs viability 
at concentrations up to 500 mg/ml (Figure 37). Among all Terminalias, the results of 
T. chebula fruit extract suggested that the inhibitory effect of the methanol extract of 
T. chebula fruit on kallikrein produced on endothelial cell surface is not due to the 
cytotoxicity to endothelial cells. Thus, methanol extract of T. chebula fruit might be 
considered a safe natural supplement inhibitor of kallikrein.  
            We have tested the two compounds from Terminalia that showed effects on 
the generation of kalikrein on HPAECs to explore their effects on HPAECs viability. 
We indicated that arjunoglucoside II significantly deceased the viability of cells only 
at high dose up to 1 mM (Figure 38), but arjunic acid induced cellular toxicity at 
concentartions equal to or greater than 300 μM (Figure 39). 
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Figure 37: Effect of Terminalia chebula fruit extract on HPAEC viability using 
the MTT assay. Bar diagrams showing the results of HPAECs viability (% of control). 
HPAECs treated by T. chebula fruit extract using the MTT assay. The wells 
containing HPAECs were treated T. chebula fruit extract for its effect on cell viability, 
and the wells containing only a complete growth medium were used as a control. 
Data represent the mean ± SEM of three experiments.  
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Figure 38: Effect of arjunoglucoside II on HPAEC viability using the MTT 
assay. Bar diagrams showing the results of HPAECs viability (% of control). 
HPAECs treated by arjunoglucoside II using the MTT assay. The wells containing 
HPAECs were treated arjunoglucoside II for its effect on cell viability, and the wells 
containing only a complete growth medium were used as a control. Data represent 
the mean ± SEM of three experiments. [*P ≤ 0.05 compare to % control]  
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Figure 39: Effect of arjunic acid on HPAEC viability using the MTT assay. Bar 
diagrams showing the results of HPAECs viability (% of control). HPAECs treated by 
arjunic acid using the MTT assay. The wells containing HPAECs were treated arjunic 
acid for its effect on cell viability, and the wells containing only a complete growth 
medium were used as a control. Data represent the mean ± SEM of three 
experiments. [*P ≤ 0.05, ****P ≤ 0.0001 compare to % control]  
 
 
 
           The aqueous extract of black tea had no significant effect on HPAECs viability 
after 1 hr treatment (Figure 40A). However, the aqueous extract of black tea 
induced a higher cytotoxicity on HPAECs compare to the control after 24 hours of 
incubation at 37 °C. The results indicated that 100 mg/ml black tea aqueous extract 
decreased cellular viability by 80% (Figure 40B). 
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Figure 40: Effect of black tea aqueous extract (1hr & 24 hrs treatments) on 
HPAEC viability using the MTT assay. Bar diagrams showing the results of 
HPAECs viability (% of control). HPAECs treated by black tea aqueous extract for 1 
hr or 24 hrs using the MTT assay. The wells containing HPAECs were treated with 
black tea aqueous extract for its effect on cell viability, and the wells containing only 
a complete growth medium were used as a control. Data represent the mean ± SEM 
of three experiments. [****P ≤ 0.0001 compare to % control]. 
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F) Effects of the aqueous extract of black tea on FXIIa-induced HPAEC 
migration:  
 
         To confirm the inhibitory effect exhibited by the aqueous extract of black tea on 
FXIIa activity, we tested the effect of the aqueous extract of black tea on FXIIa-
induced HPAEC migration. Evidence suggests that FXII stimulates the proliferation 
of endothelial cell (Gretchen A. LaRusch et al. 2010). FXII was found to significantly 
affect cell migration in the low nanomolar range (60 to 240 nM). Contact of plasma 
with the negatively charged surfaces results in binding and autoactivation of FXII to 
FXIIa (Moreau ME et al. 2005). 
          To determine at which concentrations the aqueous extract of black tea itself 
can inhibit HPAEC migration, we investigated the concentration-dependent effects of 
the aqueous extract of black tea ranging from 5 to 100 mg/ml. The aqueous extract 
of black tea significantly inhibited HPAECs migration only at 100 mg/ml (Figure 41).  
Since the aqueous extract of black tea did not inhibit HPAECs migration at 
concentrations up to 50 mg/ml, we assessed the effect of 50 mg/ml black tea 
aqueous extract on FXIIa-induced HPAEC migration. We found that 50 mg/ml was 
significantly inhibited FXIIa-induce HPAEC migration confirming our previous finding 
on the effect of black tea aqueous extract on FXIIa activity in fluid phase (Figure 42).  
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Figure 41: Effects of black tea aqueous extract on HPAEC migration. HPAECs 
were seeded in a 96-well plate and incubated overnight at 37 °C to achieve 
confluence. Then a denuded area was created with a pipette tip. Next, the plate was 
incubated with increasing concentrations of black tea extract for 24 hrs and pictures 
were taken at 0 hr and 24 hrs. Data represent the mean ± SEM of three 
experiments. [****P ≤ 0.0001 compare to control]  
 
 
 
G) Effects of natural product extracts and/or their bioactive compounds on 
FXIa activity:  
           Investigations were performed to determine selective inactivation of the serine 
protease FXI by the methanol extract of Terminalia chebula fruit. FXI is produced in 
the liver as a zymogen and circulates in human plasma in complex with HMWK at an 
approximate concentration of 3-7 μg/ml (Bouma, B.N et al. 1977; Roger C. Wiggins 
et al. 1977; Thompson, R. E et al. 1977). Thus, we tested the effect of Terminalia 
compounds on FXIa activity in fluid phase (Table 5).   
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Figure 42: Effects of black tea aqueous extract on FXIIa-induced HPAEC 
migration. HPAECs were seeded in a 96-well plate and incubated overnight at 37 
°C to achieve confluence. Then a denuded area was created with a pipette tip. Next, 
the plate was incubated with FXIIa (240 nM) in the presence and absence of 10 or 
50 mg/ml black tea extract and pictures were taken at 0 hr and 24 hrs (pictures are 
shown). Data represent the mean ± SEM of three experiments. [****p ≤ 0.0001 
compare to Control, ####p ≤ 0.0001 compare to FXIIa (240 nM)]. 
 
           We next studied the effects of the methanol extract of T. chebula fruit on FXI 
activation on endothelial cell surface.  To determine the effect of the methanol 
extract of T. chebula fruit on FXIa activity on endothelial cells, HPAEC were treated 
with 80 nM HMWK, followed by slow increase in the concentrations of T. chebula 
fruit extract in the presence of 40 nM FXI. The activity of FXIa on HPAEC was 
assessed by the S2366 substrate hydrolysis. We found that T. chebula fruit extract 
blocked FXIa activity on endothelial cells with an IC50 value of 35 mg/ml (Figure 43). 
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Figure 43: Effects of Terminalia chebula fruit extract on FXIa activity on 
endothelial cells. HPAECs were incubated with HMWK (80 nM) for 1 hr at 37 °C. 
Then the cells were incubated with FXI (40 nM) in the presence of increasing 
concentrations of T. chebula fruit extract for 1 hr at 37 °C. Next, the cells were 
incubated with S2366 (0.5 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed 
S2366 was detected at 405 nm. Data represent the mean ± SEM of three 
experiments.  
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Table 5: Summary of effects of Terminalia compounds on plasma kallikrein, FXIIa, 
FXIa and rPRCP 
 
Terminalia Compounds Structure 
Inhibitory % at 300 µM 
Kallikrein FXIIa FXIa rPRCP 
Arjunglucoside II 
 
NE 52 NE NE 
Arjunic acid 
 
 
NE NE NE NE 
Terminolic acid 
 
 
NE NE NE NE 
Arjungenin 
 
 
NE NE NE NE 
Arjunglucoside I 
 
 
NE NE NE NE 
  60 
Chebuloside II 
 
NE NE 30 NE 
Arjunolic acid 
 
NE NE NE NE 
Corilagin 
 
 
NE NE 30 NE 
Gallic acid 
 
NE NE 45 NE 
Gallic acid methyl ester 
 
NE NE NE NE 
Shikimic acid 
 
NE NE NE NE 
Ellagic acid 
 
 
NE NE NE NE 
  61 
Chebulagic acid 
 
NE NE 25 NE 
Chebulinic acid 
 
NE NE 50 NE 
2, 3, 6-tri-O-galloyl--
D-Glucose 
 
 
NE NE 45 NE 
1, 2, 3, 6-tetra-O-
galloyl--D-Glucose 
 
NE NE 52 NE 
1,2,3,4,6-penta-O-
galloyl--D-Glucose 
 
NE NE NE NE 
 
 
 
 
NE: no effect 
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Table 6: Summary of effects of red yeast rice compounds on plasma kallikrein, 
FXIIa, FXIa and rPRCP 
 
RYR compounds Structure 
Inhibitory % at 300 µM 
Kallikrein FXIIa FXIa rPRCP 
(R)-6-(2-((1S, 2S)-
2,6-dimethyl-1,2-
dihydronaphthalen-
1-yl)ethyl)-5,6-
dihydro-2H-pyran-2-
one 
 
 
 
 
 
 
 
 
 
 
NE NE NE 25 
α,β-Dehydrodihydro 
monacolin K 
 
 
 
 
 
NE NE 40 NE 
Dehydromonacolin 
K 
 
 
 
NE 15 NE NE 
Dehydromonacolin L 
 
 
 
 
 
 
 
NE NE 15 20 
  63 
Monacolin K 
(Lovastatin) 
 
 
 
 
 
NE NE NE NE 
Dihydromonacolin K 
 
 
 
 
 
 
NE NE 55 NE 
(6R)-6-(2-((1R, 2R, 
3S, 6R)-3-hydroxy-
2,6-dimethyl-
1,2,3,5,6,7,8,8a-
octahydronaphthale
n-1-yl)ethyl)-5,6-
dihydro-2H-pyran-2-
one 
 
 
 
 
 
 
 
NE NE NE 32 
Monascusazaphilol 
 
 
 
 
NE 15 NE NE 
  64 
2H-Pyran-2-one, 6-
[2-(1,2-dihydro-2,6-
dimethyl-1-
naphthalenyl)ethyl]
tetrahydro-4-
hydroxy-, [4R-[4α,
6β(1S*,2S*)]] 
 
 
 
 
NE NE 15 35 
(2S)-(3R, 4S, 6S , 
7R, 8S)-4,6-
dihydroxy-3,7-
dimethyl-8-(2-((R)-6-
oxo-3,6-dihydro-2H-
pyran-2-yl)ethyl)-
1,2,3,4,6,7,8,8a-
octahydronaphthale
n-1-yl 2-
methylbutanoate 
 
 
 
 
NE NE 15 NE 
Hydroxy-3,5-
dihydromonacolin L 
 
 
 
 
NE NE 15 25 
(4R, 6R)-4-hydroxy-
6-(2-
((1R,2R,3R,6R)-3-
hydroxy-2,6-
dimethyl-
1,2,3,5,6,7,8,8a-
octahydronaphthale
n-1-
yl)ethyl)tetrahydro-
2H-pyran-2-one 
 
 
 
 
NE 20 NE NE 
β, δ-dihydroxy-7-[l 
,2,3,5,6,7,8,8a-
octahydro-3,5-
dihydroxy-2,6-
dimethyl- 
8-(2-methyl-
butyryloxy)-
naphthalen- 1 -yl]-
heptanoic acid δ-
lactone 
 
 
 
 
 
NE 25 NE NE 
  65 
Dihydromonacolin L 
 
 
 
 
NE 15 40 NE 
1-
Naphthalenepropan
oic acid, 1,2,4a,5,6,
7,8,8a-octahydro-2,
6-dimethyl-(1S,2S,
4aR,6R,8aS)- 
 
 
 
 
NE 35 55 NE 
(9S,10R,11E,13R)-
9,10,13-
trihytroxyoctadec-
11-enoic acid 
 
 
NE NE NE NE 
 
        
 
             RYR extract has a cholesterol lowering properties. It is composed of 13 
natural statins, unsaturated fatty acids, ergosterol, amino acids, flavonoids, alkaloid 
and trace element. The previous studies have indicated the lipid lowering and anti-
inflammatory properties of xuezhikang, a commercial RYR extract preparation 
(Heber D et al. 1999). We tested the effects of RYR extract as well as its pure 
compounds on plasma kallikrein, FXIa, FXIIa and rPRCP. The results indicated that 
RYR extract has no effects on plasma kallikrein (Figure 44), FXIIa (Figure 45) and 
FXIa, with a minor inhibitory effect on rPRCP 30% inhibition at 200 mg/ml (Figure 
46).  
NE: no effect 
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Figure 44: Effect of red yeast rice extract on plasma kallikrein activity. 
Increasing concentrations of RYR extract was incubated with Kallikrein (2 nM) and 
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was 
detected at 405 nm. Data represent the mean ± SEM of three experiments. 
 
 
 
Figure 45: Effect of red yeast rice extract on FXIIa activity. Increasing 
concentrations of RYR extract were incubated with FXIIa (17 nM) and S2302 (0.4 
mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was detected at 405 
nm. Data represent the mean ± SEM of three experiments.  
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Figure 46: Effect of red yeast rice extract on rPRCP activity. Increasing 
concentrations of RYR extract was incubated with rPRCP (30 µg/ml) and the 
substrate APpNA (0.3 mM) for 1 hr at 37 °C. The absorbance of paranitronilide was 
detected at 405 nm. Data represent the mean ± SEM of three experiments. 
 
 
        During the course of screening of the RYR pure compounds on kallikrein, FXIa 
and FXIIa, three of them showed inhibitory effects on FXIa (Table 6). Accordingly, 
we decided to determine whether their effects are concentration dependent. 
The results indicated that dihydromonacolin K (Figure 47, Tables 6 & 9), 1-
naphthalenepropanoic acid 1,2,4a,5,6,7,8,8a-octahydro-2,6-dimethyl-(1S,2S,4aR,
6R,8aS) (Figure 47, Tables 6 & 9) and α,β-dehydrodihydromonacolin K (Figure 47, 
Tables 6 & 9) have inhibitory effects with IC50 values of 260, 270 & 400, respectively.  
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Figure 47: Effects of RYR active compounds on FXIa activity. Increasing 
concentration of the RYR pure compounds (1 µM to 1000 µM) were incubated with 2 
nM of FXIa and 0.291 mM of the substrate (Glu-Pro-Arg-p-Nitroanilide, S2366) in 
HEPES buffer for 1 hr at 37 ºC. Then the substrate hydrolysis was assessed 
spectrophotometrically at 405 nm. Data represent the mean ± SEM of three 
experiments.  
 
 
 
 
 
 
 
 
  69 
 
 
 
 
Figure 48: Effects of RYR active compounds on FXIa activity on endothelial 
cells. HPAECs were incubated with HMWK (80 nM) for 1 hr at 37 °C. Then the cells 
were incubated with FXI (40 nM) in the presence of increasing concentrations of 
RYR compounds for 1 hr at 37 °C. Next, the cells were incubated with S2366 (0.5 
mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2366 was detected at 405 
nm. Data represent the mean ± SEM of three experiments.  
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IV-DISCUSSION 
              Investigations revealed for first time the effects of some important natural 
product extracts on kallikrein-kinin system. The major findings of this study are: (1) 
methanol extracts of different Terminalia species (T. arjuna fruit, T. arjuna bark, T. 
bellirica fruit, T. brownii bark and T. chebula) inhibited plasma kallikrein, PK 
activation on endothelial cell surfaces, FXIIa and rPRCP activities; (2) methanol 
extract of T. chebula fruit abolished the activation of FXI to FXIa on endothelial cell 
surfaces; (3) arjunoglucoside II and arjunic acid from Terminalias inhibited FXIIa 
activity; (4) aqueous extract of black tea inhibited the activities of plasma kallikrein, 
FXIIa, rPRCP and FXIIa-induced endothelial cell migration; (5) dihydromonacolin K, 
1-naphthalenepropanoic acid 1,2,4a,5,6,7,8,8a-octahydro-2,6-dimethyl-(1S,2S,4aR,
6R,8aS) and α,β-dehydrodihydromonacolin K from red yeast rice inhibited the 
activity of FXIa. 
              Plasma kallikrein is implicated in the pathological processes inflammation 
and HAE through different systems plasma Kallikrein-Kinin, complement and 
fibrinolytic systems. These systems are regulated in plasma mainly by C1-INH. C1-
INH inhibits FXIIa and kallikrein (Pixley et al., 1985). In addition, C1-INH inhibits the 
activation of the complements C1r and C1s in the complement system. In HAE, 
mutations of C1-INH gene cause a reduction in the levels of functional C1-INH 
protein, leading to an overproduction of BK. 
            Plasma kallikrein hydrolyzes HMWK to release the potent proinflammatory 
peptide BK.  BK mediates its effects mainly via B2R (Leeb-Lundberg LM et al., 2005; 
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Marceau F et al., 1998). The binding of BK to B2R on endothelial cells results in an 
increase in the intracellular Ca2+ levels and subsequent production of endogenous 
vasodilators NO and PGI2 causing an increase in vascular permeability and edema 
(Zhao et al., 2001; Hong, 1980; Palmer et al.1987). The deficiency of C1-INH results 
in reduced levels of plasma PK and HMWK (Gigli I et al., 1975; Trumpi-Kalshoven et 
al., 1978; Gallimore et al., 1979). BK is responsible for most of the symptoms 
associated with the edema in patients with acute HAE attacks (Nussberger et al. 
2002). Undoubtedly, BK is deeply implicated in the pathophysiology and clinical 
manifestations of HAE.  
           We have screened several natural plant extracts listed in (Table 4) for their 
effects on FXIIa, kallikrein and rPRCP in the liberation of BK from HMWK that could 
be used for the purpose of HAE management. These natural products were selected 
based on their anti-inflammatory and cardiovascular effects reported in the literature 
as well as their safety and availability. Using a selected concentration 200 mg/ml, we 
explored the inhibitory effects of those extracts and accordingly continued our study 
on the extracts that showed the most promising effects. Methanol extracts of 
different species of Terminalia were tested for their inhibitory effects on plasma 
kallikrein activity in fluid phase using 200 mg/ml of each. T. arjuna fruit, T. bellirica 
fruit, T. brownii bark and T. chebula fruit significantly blocked the proteolytic activity 
of plasma kallikrein activity in fluid phase by 45%, 65%, 45% and 85%, respectively 
(Figure 5). In contrast, T. arjuna bark extract did not show a significant inhibitory 
effect on plasma kallikrein at the same concentration (Figure 5). The aqueous 
extract of black tea was selected for study for two main reasons, its significant anti-
inflammatory effect (Chatterjee P et al. 2012) and the high consumption of black tea, 
in which it is considered one of the most common beverages worldwide (Graham 
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H.N et al. 1991; Monika Mueller. 2010). At 200 mg/ml, it was indicated that black tea 
aqueous extract in fluid phase significantly inhibited the hydrolysis of S2302 by 
plasma kallikrein by 55%. At the same selected concentration, methanol extracts of 
some other natural product extracts also significantly inhibited plasma kallikrein 
activity; black pepper (35%) and cardamom (30%), cayenne pepper (15%), clove 
(15%), cumin (25%), poppy seed (50%), dill (20%), garlic (15%), ginger (17%) and 
rosemary (17%) (Figure 5). The methanol extract of red yeast rice was also tested 
on plasma kallikrein activity and showed no effect (Figure 5). Initial studies showed 
that the methanol extracts of Terminalia species and the aqueous extract of black 
tea exhibited the highest inhibitory effects toward plasma kallikrein activity.  
             In the traditional Ayurvedic medicines, T. arjuna bark was used for different 
purposes including antidyslipidemic, anti-inflammatory, antioxidant and maintaining  
heart functions by strengthening and improving cardiac muscles (Chander R et al, 
2004; Maulik SK et al. 2012). Although T. arjuna bark has no effects on kallikrein at 
highest concentrations, studies were done to compare it with other species. 
            The results indicated that T. arjuna fruit, T. arjuna bark, T. bellirica fruit, T. 
brownii bark and T. chebula fruit inhibited plasma kallikrein activity with IC50 values of 
220, 280, 65, 240 and 30 mg/ml, respectively (Figures 6, 7, 8, 9 & 10). T. arjuna 
bark showed stimulatory effects at lower concentrations, but at higher concentrations 
blocked plasma kallikrein activity. Among all the species tested, T. chebula fruit has 
shown the highest inhibitory effect on plasma kallikrein activity. We also determined 
the effects of Terminalias pure compounds. Compounds isolated from T. bellirica 
fruit were chebulagic acid, gallic acid, gallic acid methyl ester, (1, 2, 3, 6-tetra-O-
galloyl--D-Glucose) and (1,2,3,4,6-penta-O-galloyl--D-Glucose). Compounds 
isolated from T. chebula fruit were arjunglucoside II, arjunic acid, terminolic acid, 
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arjungenin, arjunglucoside I, chebuloside II, arjunolic acid, shikimic acid and ellagic 
acid. Three compounds were isolated from both T. bellirica fruit and T. chebula fruit 
were corilagin, chebulinic acid and (2, 3, 6-tri-O-galloyl--D-Glucose). At 300 μM, all 
tested compounds showed no inhibitory effects on plasma kallirein in fluid phase. 
Some compounds instead showed minor stimulatory effects on plasma kallikrein 
compared to the control. These include arjunolic acid and ellagic acid (from T. 
chebula fruit), 1,2,3,4,6-penta-O-galloyl--D-Glucose and gallic acid methyl ester 
(from T. bellerica fruit) with stimulatory effects of 19%, 26%, 16% and 13%, 
respectively. Ellagic acid showed the highest stimulatory effect on plasma kallikrein 
activity in fluid phase. Ellagic acid was also isolated from T. bellerica fruit (Pfundstein 
B et al. 2010). In addition, gallic acid and its derivatives such as (1,2,3,4,6-penta-O-
galloyl--D-glucose) are predominant polyphenols in the methanol extract of T. 
bellerica fruit compare to T. chebula fruit. The greater presence of compounds with 
minor stimulatory effects on plasma kallikrein in T. bellerica than T. chebula probably 
explains the lower inhibitory effect of T. bellerica (IC50 value of 65 mg/ml) compare to 
T. chebula (IC50 value of 30 mg/ml) through their weak stimulatory effects. The 
presence of these stimulatory compounds in very low concentrations in the extracts 
probably allowed the inhibitory effects of the extracts to outweigh their minor plasma 
kallikrein stimulatory effects. The inhibitory effects exhibited by Terminalias extracts 
versus the isolated compounds could be due to the positive interactions between the 
components, in which the pharmacodynamic synergy might be crucial for their 
effects. The aqueous extract of black tea also blocked the activity of plasma 
kallikrein with an IC50 value of 220 mg/ml (Figure 11). 
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Table 7: Summary of effects of natural product extracts on Kallikrein formed on      
HPAEC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Plant extracts 
Inhibition of Kallikrein formed on 
HPAEC surface 
IC50 values (mg/mL) 
Anise 90 
Basil 100 
Black Pepper 500 
Cinnamon NE 
Coriander 250 
Fennel NE 
Mentha 300 
Poppy seed 300 
Thyme 175 
Black tea 400 
Terminalia 
T. arjuna fruit 20 
T. arjuna bark 160 
T. bellirica fruit 20 
T. brownii bark 80 
T. chebula fruit 15 
Red yeast rice NE 
NE: no effect 
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Table 8: Summary of effects of natural product extracts on Kallikrein, FXIIa and 
rPRCP 
 
Plant extract 
% kallikrein 
inhibition 
(200 mg/ml) 
% rPRCP 
Inhibition 
(200 mg/ml) 
% FXIIa 
Inhibition 
 (200 mg/ml) 
Anise NE 30 20 
Basil NE 50 55 
Black Pepper 35 30 NE 
Cinnamon NE 70 65 
Coriander NE 25 NE 
Fennel NE 52 NE 
Mentha NE 45 30 
Poppy seed 50 22 NE 
Thyme NE 23 NE 
Black tea 55 60 80 
Terminalia 
T. arjuna fruit 45 65 55 
T. arjuna bark NE NE 55 
T. bellirica fruit 65 NE 90 
T. brownii bark 45 NE 20 
T. chebula fruit 85 80 98 
Red yeast rice NE NE NE 
 
 
 
 
 
 
 
 
 
 
NE: no effect 
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 The major black tea compounds included epigallocatechin gallate (EGCG), 
epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin (EC), caffeine and 
quercetin, which showed no inhibitory effects on plasma kallikrein activity (Figure 
32). We have also tested black tea extract with more than 80% theaflavins 
(theaflavin and theaflavin gallates) and also showed no effect. In conclusion, our 
data suggest that Terminalias and black tea extracts have specific effects on the 
components of KKS. In addition, our data indicate the presence of uncharacterized 
inhibitor(s) of kallikrein. All Terminalias methanol extracts (except T. arjuna bark) as 
well as the black tea aqueous extract inhibited plasma kallikrein activity. The results 
indicated that T. chebula fruit extract showed the highest inhibitory effect on plasma 
kallikrein activity with an IC50 value of 30 mg/ml (Figure 10). 
            Plasma kallikrein is produced and released from the liver as a zymogen 
(prekallikrein) that is circulated in plasma as a complex with HMWK, which functions 
as a cofactor for the activation PK (Kaplan AP et al. 2003). The assembly of the 
HMWK-PK complex on endothelial cell surfaces resulted in a rapidly activation of PK 
to kallikrein. This activation is mediated by the interaction of HMWK with a complex 
of several proteins including cytokeratin 1, gC1qR as well as urokinase plasminogen 
activator receptor (uPAR) (Joseph K et al. 1999; Mahdi F et al. 2001).  
The results indicated that the methanol extracts of the Terminalia species and the 
aqueous extract of black tea blocked the activity of plasma kallikrein in fluid phase. 
Next, we determined the pharmacological effects of the methanol extracts of the 
Terminalia species and the aqueous extract of black tea on the formation of kallikrein 
on endothelial cells (HPAEC). The investigations indicated that T. arjuna fruit, T. 
arjuna bark, T. bellirica fruit, T. brownii bark and T. chebula fruit inhibited the 
kallikrein produced on HPAEC with IC50 values of 20 and 160, 20, 80 and 15 mg/ml, 
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respectively (Figures 12, 13, 14, 15 & 16). We also indicated that the aqueous 
extract of black tea blocked kallikrein formed on endothelial cells (HPAEC) with an 
IC50 value of 400 mg/ml (Figure 19). The inhibitory effects of these extracts might be 
due to either directly blocking effects on the activity of kallikrein produced by the 
activation of the HMWK-PK complex on HPAEC or due to interference with the 
assembly of this complex on HPAEC surfaces. In conclusion, all Terminalias 
methanol extracts as well as the black tea aqueous extract abolished kallikrein 
generation on HPAEC surfaces. 
           In HAE patients, the reduction in the C1-INH levels causes overproduction of 
FXIIa to initiate a contact system leading to a local production of BK (Moreau ME et 
al. 2005; Weiss R et al. 1986). Thus, studies indicated that FXIIa might be implicated 
in HAE disease either through converting PK to kallikrein or activating of its 
autoactivation cycle producing more FXIIa, and ultimately up-regulates kallikrein 
generation (Kaplan AP et al. 2003; Fernando LP et al. 2003). It was reported that 
PRCP and Heat Shock Protein-90 (HSP90) could also directly activate PK to 
kallikrein on endothelial cells independently from FXII-activation pathway (Shariat-
Madar et al. 2002; Joseph K et al. 2009). Thus, PRCP-dependent PK activation 
might be considered as an additional BK-forming mechanism leading to additional 
NO and PGI2 production. Several stimuli were found to activate PK to kallikrein on 
endothelial cells such as FXIIa and PRCP, we determined whether Terminalias 
methanol extracts as well as the black tea aqueous extract could inhibit FXIIa and 
rPRCP activities in fluid phases. Our results indicated that T. chebula fruit also 
showed the highest inhibitory effect on FXIIa activity in fluid phase with IC50 value of 
30 mg/ml compared to the effects of T. arjuna fruit, T. arjuna bark and T. bellirica fruit 
which blocked FXIIa activity with IC50 values of 190, 190 and 50 mg/ml, respectively 
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(Figures 20, 21, 22 & 23). The results also indicated that T. brownii bark showed the 
weakest inhibitory effect with only 27% reduction in the activity of FXIIa at 
concentration up to 300 mg/ml (Figure 24). Investigation of the Terminalias pure 
compounds revealed that the triterpene glucoside, arjunoglucoside II and an 
aglycone terpenoid, arjunic acid blocked the activity of FXIIa activity with IC50 values 
of 370 and 780 µM, respectively (Figures 26 & 27). The study also indicated that 
ellagic acid and (1,2,3,4,6-penta-O-galloyl--D-glucose) increased FXIIa activity by 
25% and 23%, respectively. Previously, it was reported that ellagic acid could 
activate FXII (Hageman factor) to FXIIa in a mechanism similar to the negatively 
charged surfaces such as glass or kaolin (Ratnoff OD and Saito H. 1982) and can be 
used as a model to induce Hageman factor activation experimentally (Ratnoff OD. 
1981). The low concentration of ellagic acid among mixture of compounds in 
Terminalias extract was not enough to interfere with extract inhibitory properties 
(Table 5). 
          On the effect of the aqueous extract of black tea on FXIIa in fluid phase, we 
found that the aqueous extract of black tea also blocked the activity of FXIIa in a 
dose-dependent manner with an IC50 value of 27 mg/ml (Figure 25).  Additionally, 
we also found that black tea pure compounds including epigallocatechin gallate 
(EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin (EC), 
caffeine and quercetin showed no inhibitory effects on FXIIa activity (Figure 32). The 
inhibitory effect of the aqueous extract of black tea on FXIIa-induced HPAEC 
migration was assessed. To determined which concentrations of black tea aqueous 
extract can inhibit HPAEC migration, a dose response was performed with 
increasing concentrations of tea 5-100 mg/ml and indicated that the aqueous extract 
of black tea significantly inhbited HPAEC migration only at concentration up to 100 
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mg/ml (Figure 41). Using the highest concentration of FXII 240 nM to induce 
HPAEC migration, it was found that the aqueous extract of black tea at 50 mg/ml 
was significantly inhibited FXIIa-induce HPAEC migration, confirming the inhibitory 
effect of black tea aqueous extract on FXIIa activity (Figure 42). On the effect of 
extracts on rPRCP activity, studies indicated that T. arjuna fruit, T. chebula fruit and 
T. brownii bark extracts blocked rPRCP activity with an IC50 values of 150, 120 and 
280 mg/ml, respectively (Figures 28, 29  & 30). T. arjuna bark and T. bellirica fruit 
did not block rPRCP activtity. Furthermore, all Terminalia pure compounds showed 
no effects on rPRCP activity. While black tea aqueous extract blocked rPRCP 
activity with IC50 values of 160 mg/ml, pure compounds epigallocatechin gallate 
(EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin (EC), 
caffeine and quercetin showed no inhibitory effects on rPRCP activity in fluid phase 
(Figures 31 & 32).  In addition to the evidence presented above, which 
demonstrates the inhibitory effects of the methanol extracts of Terminalias and the 
aqueous extract of black tea on kallikrein activity, we were interested in determining 
whether Terminalias and black tea aqueous extracts are capable of reducing cell 
viability. While T. arjuna fruit showed no significant effects on HPAECs viability 
(Figure 33), T. arjuna bark significantly reduced HPAECs viability by 40% at 
concentrations as low as 30 mg/ml using cell survival ratio using the MTT assay 
(Figure 34). A previous study indicated that T. arjuna fruit extract was capable of 
maintaining hepatocytes viability and reducing cadmium-induced hepatic oxidative 
stress using the MTT assay (J. Ghosh et al. 2010). In the present study, we 
confirmed the capability of T. arjuna fruit extract to maintain cell viability of HPAECs 
using the MTT assay. Our finding also confirmed that a component of T. arjuna fruit 
is an inhibitor of kallikrein. On the other hand, T. bellirica fruit and T. brownii bark 
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were significantly toxic to HPAECs in which T. bellirica fruit exhibited a cytotoxic 
effect in a dose-dependent manner and T. brownii bark reduced HPAECs viability at 
concentrations as low as 20 mg/ml by approximately 40% indicating its highly toxic 
effect on endothelial cells (Figures 35 & 36). Interestingly, T. chebula fruit extract 
exhibited no effects on HPAECs viability at concentrations up to 500 mg/ml (Figure 
37). A previous study reported that T. chebula fruit extract significantly decreased rat 
pheochromocytoma cells (PC12) death induced by oxygen-glucose deprivation 
followed by reoxygenation (OGD-R), H2O2 and LPS suggesting a protective effect of 
T. chebula fruit extract through its antioxidant and antiinflammatory properties (Gaire 
BP et al. 2013). In this study, we confirmed that T. chebula fruit extract was capable 
of maintaining cell viability of HPAECs using the MTT assay (Figure 37). Among all 
Terminalias, the results of T. chebula fruit extract suggested that the inhibitory effect 
of the methanol extract of T. chebula fruit on kallikrein produced on endothelial cell 
surfaces is not due to a direct cytotoxic effect to endothelial cells.  
            While arjunoglucoside II significantly deceased the viability of cells only at 
high dose up to 1 mM (Figure 38), arjunic acid reduced HPAEC viability by 20% at 
concentration 300 μM and by approximately 100% at 1 mM (Figure 39). The 
investigation revealed that black tea aqueous extract has no significant effect on 
HPAECs viability after 1 hr treatment. On the contrary, HPAECs viability was 
significantly reduced by approximately 80% at concentrations starting from 100 
mg/ml after 24 hours treatment (Figure 40). Taken all together, our data indicated 
that the extracts of T. chebula fruit and T. arjuna fruit were capable of inhibiting kinin-
generating enzymes and did not contain cytotoxic factors for HPAEC at the effective 
concentrations. 
         In order to further characterize the selectivity of the most active extract T. 
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chebula fruit extract to plasma kallikrein and also due to the structural similarities 
between plasma kallikrein and FXIa, we have determined the ability of T. chebula 
fruit extract to inhibit the activation of FXI to FXIa on HPAEC surfaces. The study 
indicated that T. chebula fruit extract blocked FXIa activity on HPAECs with an IC50 
value of 35 mg/ml (Figure 43). We also tested the effects of Terminalias compounds 
on FXIa activity in fluid phase.  
Table 9: Summary of the pure secondary metabolites identified in our study 
Plant 
source 
Compounds Structure 
Inhibitory effects with IC50 (µM) 
Kallikrein FXIIa FXIa rPRCP 
Terminalia 
Arjunoglucoside II 
 
 
 
NE 370 NE NE 
Ajunic acid 
 
 
NE 780 NE NE 
Red yeast 
rice 
α,β-
Dehydrodihydromon
acolin K 
 
 
 
NE NE 400 NE 
Dihydromonacolin K 
 
 
 
NE NE 260 NE 
1-
Naphthalenepropan
oic acid, 1,2,4a,5,6,
7,8,8a-octahydro-2,
6-dimethyl-(1S,2S,
4aR,6R,8aS) 
 
 
 
 
NE NE 270 NE 
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             The results indicated that chebuloside II, corilagin, gallic acid, chebulagic 
acid, chebulinic acid, (2, 3, 6-tri-O-galloyl--D-Glucose) and (1, 2, 3, 6-tetra-O-
galloyl--D-glucose) blocked FXIa activity by 30%, 30%, 45%, 25%, 50%, 45% and 
52% at 300 μM, respectively (Table 6). In conclusion, our data demonstrated that T. 
chebula fruit also have an affinity for FXIa. Thus, this extract might be used safely as 
a supplement to improve the anticoagulant effects.              
             The extract of RYR had a cholesterol lowering effect, and different RYR 
preparations are commerciallly available. The lipid lowering and anti-inflammatory 
properties of xuezhikang, a commercial RYR extract preparation, were confirmed 
(Heber D et al. 1999). The extract of RYR had pharmacologically active constituents 
including thirteen natural statins. Thus, we have tested the effects of RYR extract as 
well as its isolated pure compounds on all enzymes of interest that are involved in 
BK liberation. We determined for the first time that RYR extract had a stimulatory 
effect on plasma kallikrein up to 20% at 10 mg/ml and exceeded 43% at 300 mg/ml. 
In a previous study, it was indicated that lovastatin, also known as monacolin K 
(RYR component) upregulates the expression of cardioprotective B2R in endothelial 
cells (Liesmaa I et al. 2007). Our findings, explored the impact of RYR extract on the 
Kallikrein-Kinin system through plasm kallikrein, the major liberator of BK from 
HMWK in human body. We also indicated that RYR extract has no effects on FXIIa 
and FXIa, whereas it has a minor inhibitory effect on rPRCP 30% inhibition at 200 
mg/ml (Figures 44, 45 & 46). The results indicated that RYR pure compounds 
showed no effects on plasma kallikrein, FXIIa and rPRCP.  Interestingly, among all 
RYR compounds, three of them named dihydromonacolin K, [1-Naphthalene 
propanoic acid 1,2,4a,5,6,7,8,8a-octahydro-2,6-dimethyl-(1S,2S,4aR,6R,8aS)] and 
NE: no effect 
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α,β-dehydrodihydromonacolin K showed inhibitory effects on FXIa activity in fluid 
phase by 55%, 55% and 40% at 300 μM, respectively (Table 6). Thus, we determined 
their IC50 values and found that dihydromonacolin K, 1-naphthalenepropanoic acid 1,
2,4a,5,6,7,8,8a-octahydro-2,6-dimethyl-(1S,2S,4aR,6R,8aS) and α,β-
dehydrodihydromonacolin K blocked FXIa activity in fluid phase with IC50 values of 
260, 270 & 400, respectively (Figures 47 & 9). Recently, FXIa inhibitor named BMS-
262084 demonstrated antithrombotic effect in rat models of arterial and venous 
thrombosis, suggesting FXIa an alternative anticoagulation target (Schumacher A et 
al. 2007). In conclusion, it was reported that RYR extract consumption is associated 
with an edema symptoms. Thus, our findings suggested that RYR extract is probably 
implicated in the appearance of edema symptoms through a plasma Kallikrein-Kinin 
mediated mechanism. In addition, we indicated novel FXIa inhibitors that could be 
used as a lead compounds for identifying more potent FXIa inhibitors that might be 
used for thrombosis management purposes. 
 
          In summary, the effects of all screened natural product extracts on plasma 
kallikrein, kallikrein formed on HPAEC, FXIIa, FXIa and rPRCP were summarized in 
Tables 7 & 8. The results indicated that among all screened natural product extracts, 
the methanol extract of T. chebula fruit and the aqueous extract black tea were 
indicated as the most promising extracts to develop inhibitors of plasma kallikrein 
and FXIIa activities. The results also suggested that the methanol extract of T. 
chebula fruit could be used as natural supplement for HAE as well as thrombosis 
managements. Additionally, five inhibitors were identified as pure inhibitors from our 
study. Two were isolated from T. chebula extract showing inhibitory effects on FXIIa 
activity and three were isolated from RYR extract showing inhibitory effects on FXIa 
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activity. Thus, we suggested that the identified inhibitors in our study (Table 9) could 
be used as lead compounds for future chemical modification work to identify more 
potent inhibitors. 
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